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During pregnancy, the placenta plays a vital role in protecting the developing fetus from microbial 
infections. The multinucleated and terminally differentiated syncytiotrophoblasts actively 
coordinate host defense through a multitude of mechanisms. In addition to forming a cellular 
barrier, the syncytiotrophoblasts release extracellular vesicles containing microRNAs from the 
chromosome 19 microRNA cluster (C19MC). These vesicle-packaged miRNAs, upon uptake by 
recipient cells, induce autophagy and limit viral infection, acting against a diverse panel of both 
DNA and RNA viruses. We have shown that medium conditioned by primary human trophoblast 
(PHT) cells, which contain these vesicles, confers resistance from pathogens associated with 
congenital infections to recipient non-placental cells. Furthermore, we have demonstrated that 
primary human trophoblasts constitutively produce interferon lambda 1 (IFNλ1), leading to a 
robust induction of interferon stimulated genes in an autocrine and paracrine manner. These 
parallel pathways, actively coordinated by PHT cells, contribute to the barrier function of the 
placenta, protecting the developing fetus from viral infections.  
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1.0  INTRODUCTION 
An infection during pregnancy can have severe consequences to a mother’s health and to her 
developing fetus [1]. Infection and inflammation are the leading causes of preterm births, which 
account for approximately 13 million pre-term births annually worldwide [2, 3] and are a major 
cause of infant mortality. Maternal infections, whether resulting from bacteria, viruses, or 
protozoa, can lead to infection during delivery or pregnancy loss, due to systemic spread [4]. 
Infections that are transmitted to the fetus can result in developmental abnormalities, fetal, or 
neonatal disease.  
The placenta, a fetal-derived organ that interfaces the mother and the fetus and coordinates 
the exchange of nutrients, waste, gas, and also the production of essential hormones, is a 
remarkably effective barrier against viral infections. While historically considered a passive barrier 
to infection, we now appreciate that the placenta actively coordinates a multitude of 
immunological responses to protect the fetus from microbial infections as well as preventing 
immune rejection of the fetus [5]. Once the placenta is formed, the main site of maternal-fetal 
interaction is the placental villi, tree-like structures that are bathed in maternal blood, and facilitate 
maternal-fetal communication. This villous tree is comprised of trophoblasts, with a core of 
fibroblasts, macrophages and fetal endothelial cells. The apical surface of the villous trees is 
covered by the terminally differentiated, multinucleated trophoblasts, known as 
syncytiotrophoblasts. These cells are in direct contact with the maternal blood, and are the point 
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of communication between the mother and the fetus. Our lab has been studying trophoblasts, 
seeking to understand their role in immunity during pregnancy, and specifically investigating how 
the syncytiotrophoblasts inhibit viral infection and confer protection to viral infection to 
neighboring non-placental cells. The cellular composition of the villi, as well as structural 
differences between the human placenta and other eutherian organisms (organisms having a 
placenta) are discussed in later sections.  
 In the following sections of this chapter, we summarize relevant aspects of human 
pregnancy, with a focus on the role of the placenta as a physical and functional barrier to infection, 
as well as review information regarding the immune system during pregnancy, and how infection 
from a diverse range of pathogens can affect the maternal and fetal health. Next, we review data 
on the expression and function of chromosome 19 miRNA cluster (C19MC), a placenta-specific 
cluster of small non-coding RNAs shown to confer antiviral effects. Lastly, we provide an 
overview on interferons, antiviral signaling proteins, focusing on their expression during 
pregnancy. Subsequent chapters will cover our recent findings regarding the role of the PHT cells 
in conferring resistance to viral infections associated with congenital diseases, the production of 
IFNλ1 by the PHT cells, and PHT cell resistance to infection by Zika virus (ZIKV). The final 
chapter will summarize our findings and the implications of the work, touching on relevance and 
potential future directions.   
1.1 INTRODUCTION TO HUMAN PREGNANCY 
Human pregnancy lasts an average of 38-42 weeks, arbitrarily divided into three trimesters, 
starting from the last menstrual period. Following fertilization of the oocyte by the spermatozoon 
 3 
in the fallopian tubes, the zygote travels to the uterus, where it implants into the maternal 
endometrium. The trophectoderm is the first tissue of the blastocyst to differentiate, eventually 
forming the extra-embryonic tissues, including the placenta. The inner cell mass of the blastocyst 
develops into the fetus. While these early developmental processes take place, the maternal body 
undergoes a wide range of physiological changes, including differentiation of the uterine 
endometrium into the decidua, hormonal changes, and shifts in the maternal immune system. 
Because the prevention of fetal rejection was considered the main function of the maternal immune 
system, pregnancy has historically been viewed as in a state of suppression, termed “pregnancy–
associated immune deficiency” [6]. It was suggested that in order to prevent rejection of the semi-
allograft fetus, the maternal immune system must be globally suppressed. However, a growing 
body of literature challenges the immune suppression hypothesis, demonstrating a complex 
regulation of maternal immunity and active coordination of innate immunity by the placenta. 
Furthermore, the local maternal immune system in the uterus has been demonstrated to remain 
competent, and play an essential role in implantation, early embryonic development, and intricate 
immune signaling that coordinates maternal-placental interactions.  
The following sections discuss the events underlying placental development, noting 
important placental structures and functions, the maternal immune system during pregnancy, and 
characterizing both the innate and adaptive responses. The consequences of microbial infections 
during pregnancy are also discussed, focusing on their impact on the fetus. These sections provide 
the necessary context for later chapters, which discuss the role of the placenta in attenuating fetal 
viral infections, and how that protection can be conferred to non-placental cells, as discussed in 
the later chapters.  
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1.1.1 The Human Placenta  
The placenta is a fetal-derived organ, resulting from the differentiation of the trophectoderm layer 
of the developing embryo, early in gestation. At term, the placenta is large discoid organ, with size 
averaging 22 cm in diameter, 2.5 cm in thickness, and usually weighing half a kilogram [7]. The 
placenta functions in gas, nutrient, and waste exchange between the mother and the fetus. 
Additionally, the placenta produces many pregnancy specific hormones, such as human chorionic 
gonadotropin (hCG), which are essential for maintaining the pregnancy. The role of the placenta 
in providing the fetus with nutrients has been known since the 5th century BC, though it was 
initially thought to act as a barrier, preventing the maternal-fetal blood mixing [8]. The term 
placenta, meaning “cake” in Latin, was proposed by Realdo Columbo in the sixteenth century, 
based on the organ’s discoid shape. In the seventeenth century, William Harvey theorized separate 
maternal and fetal circulations, which was then proven in the eighteenth century by William and 
John Hunter, using molten wax to model the utero placental vessels and distinct circulatory 
systems [7, 9, 10]. Weber and Dalrymple later expanded on the descriptions of the placental 
anatomy, characterizing the placental villi and the capillary structures. This was then followed by 
identification of the trophoblast bilayer in 1882 by Langhans. William Carpenter’s experiments in 
1889 defined the intervillous space [11]. Ambrosius Hubrecht in 1889 defined and named the 
tissue barrier between the maternal and fetal circulations trophoblast (nutrition and germ), due to 
the importance of nutrient exchange between the mother and the fetus [12].  
1.1.1.1 Placental Structure 
The fetus is connected to the placenta by the umbilical cord, which contains two umbilical arteries 
and an umbilical vein. The maternal side of the placenta, referred to as the basal plate, is in direct 
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contact with the decidua, the lining of the uterus. The villus is the main functional unit of the 
placenta. Each villus is comprised of an outermost layer of cells, the syncytiotrophoblasts. Directly 
subjacent to the syncytiotrophoblasts are the mononuclear cytotrophoblasts, which become a 
discontinuous layer after the first trimester. The villous stroma comprises fibroblasts, as well as 
placental macrophages known as Hofbauer cells. In the stroma are fetal blood vessels lined by 
endothelial cells. The uterine walls are comprised of a layer of smooth muscle tissue, known as 
the myometrium, which is responsible for uterine contractions. Internal to the myometrium is the 
decidua, which forms the anchoring point for the placenta, and is shed after parturition. At the site 
of implantation, the extravillous trophoblasts invade the decidua and inner third of the 
myometrium. These structural features of the placenta are depicted in figure 1-1, below.  
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Figure 1-1 - Structure of the Human Placenta (A) A schematic of a human fetus, surrounded by amniotic fluid, 
attached to the placenta by the umbilical cord. (B) Enlarged view of one of the villous trees, demonstrating the 
anchoring villi as well as the floating villi. The placenta attaches to the maternal decidua. Adjacent to the 
decidua is the myometrium. The villus is surrounded by intervillous space, perfused with maternal blood. The 
umbilical cord attaches the fetus to the chorionic plate. The basal plate contacts the decidua. (C) An enlarged 
view of the villus tree. Extravillous (intravascular) trophoblasts (EVT) are depicted invading the maternal 
spiral artery. Adjacent to the EVTs are uterine natural killer cells (uNK). The distal cells of the villus tree are 
syncytiotrophoblasts, which produce and secrete hormones, such as human chorionic gonadotropin (hCG). The 
syncytiotrophoblasts are the site of maternal fetal interaction, with exchange of nutrients, waste, gases, and 
hormones. Subjacent to the syncytiotrophoblasts are the cytotrophoblasts. (From Delorme-Axford et al., 2014 
[13]; modified, with permission, from Annual Reviews 2014.)  
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1.1.1.2 Placental Development 
During early blastocyst development, the extra-embryonic trophoblast cell lineage is the first to 
develop. 6-7 days after fertilization, the blastocyst attaches to the uterine endometrium, beginning 
implantation [14]. At this stage, the blastocoel and the inner cell mass are surrounded by a single 
layer of mononuclear cells. The cells overlaying the inner cell mass form the contact point with 
the endometrium. At 7-8 days post fertilization, the trophoblasts that attach to the endometrium 
fuse laterally, forming the first multinucleated syncytiotrophoblasts. This process is completed by 
day 11 after implantation, as a fully formed syncytium covers the entire implanted blastocyst [15]. 
Days 8-12 after fertilization, the lacunas begin formation, which will eventually give rise to the 
intervillous space.  
Concurrent with lacunar formation, the endometrial cells regrow to cover the placenta, and 
the inner cell mass begins to differentiate into the three germ layers. The lacuna formation 
partitions the trophoblasts into three major sections. The first is the chorionic trophoblasts near the 
embryo, which will form the chorionic plate. The second section is the lacunar zone, which will 
become the intervillous space. The third section is made up of the trophoblastic shell, which 
interacts with the endometrium to produce the basal plate [7]. Around day 12 after fertilization, 
the progenitor extravillous trophoblasts begin to invade each of these three layers, extending both 
laterally and deeply into the endometrium. Some of the invasive trophoblasts give rise to 
endovascular trophoblasts, remodeling the maternal spiral arteries and replacing the vascular 
smooth muscle. This permanently dilates the spiral arteries, preventing their constriction, causing 
reduced perfusion pressure of the placental bed [16, 17].  
The proliferating cytotrophoblasts increase the partitions and branching, leading to the 
development of the primary villi. The surrounding trabeculae will eventually form the intervillous 
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space. The villous core is formed by the penetration of the extraembryonic mesoderm, with the 
cytotrophoblasts at the distal end. These columns invade into the maternal uterine capillaries. The 
proliferation of the columnar cells supplies the extraembryonic trophoblasts. The hemangioblastic 
progenitors, an undifferentiated and proliferating cell type, become the source for the developing 
early fetal capillaries endothelial cells [18]. Trophoblastic columns invade maternal vessels, 
plugging the distal segments, and therefore blocking maternal and fetal circulation, which 
maintains a state of hypoxia [19, 20]. After 8-9 weeks, the plugs begin to lyse, starting at the 
periphery and progressing centripetally, beginning the perfusion of the placental intervillous space 
with maternal blood.  
1.1.1.3 Placental functions 
The placenta’s predominant function is to regulate the maternal-fetal exchange of gases, supply of 
nutrients, and removal of waste, to produce hormones, and to provide immunological defense [21, 
22]. The syncytiotrophoblasts are key players in these processes, and facilitate the transfer of 
molecules across two plasma membranes. The transcellular transport across the syncytium occurs 
via non-mediated transport, mediated transport, or endocytosis. Non-mediated transport relies on 
the physical and chemical properties of the molecules, rather than a specific transport mechanism. 
Mediated transport is more common, relying on transporter proteins present at the plasma 
membrane, such as transport of glucose via the glucose transporters (GLUT family) [23], present 
at the microvillous membrane and basement membrane. The process of endocytosis involves the 
formation of vesicles through invagination at the plasma membrane. When transporting cargo to 
the fetal blood, these vesicles are transported to the basal side of the cell, where they fuse and 
release their cargo. Endocytosis transport is important for the transfer of maternal IgG to the fetus 
[24]. 
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A key function of the placenta is the production of critical hormones that are needed for 
proper maintenance of the pregnancy. The syncytiotrophoblasts produce large quantities of 
hormones including hCG, human placental lactogen (hPL), and many other growth factors, such 
as insulin like growth factor (IGF-1), transforming growth factor beta (TGFβ), and epidermal 
growth factor (EGF) [25].  
It is now appreciated that the placenta also functions as a physical and functional barrier to 
infection. Although previously suggested to be a passive barrier, lacking many of the receptors 
necessary for pathogen entry [5], we now know that the placenta actively coordinates an immune 
response. Furthermore, recent studies have demonstrated that the placenta is able to detect and 
respond to microbial infections, mounting a coordinated immune response. This is discussed in 
more detail in the following sections.   
1.1.1.4  Modeling the placenta 
Certain aspects of human pregnancy and placental function can be determined by observations 
from non-invasive procedures and post-pregnancy examination. For example, ultrasound is used 
to image placental structure during routine pre-natal care, and can also be used to measure placental 
perfusion with maternal blood [7, 26]. Other biomarkers of pregnancy can be found in maternal 
blood, and can be used for indicators of potential disease states [27-29]. With regards to studying 
infections during pregnancy, many retrospective and case studies have been used to assess the 
health of the mother and fetus in the presence of infections, such as with HIV or Zika [27, 30-33]. 
These studies can include placental biopsies, where histological examination of the placenta 
provides information about infection or immune cell infiltration.  
In order to study the mechanisms underlying vertical transmission of infections, a number 
of different animal models can be used, with advantages and disadvantages to each. Mouse models 
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of infection during pregnancy allow researchers to understand the mechanisms of trans-placental 
infections as well as fetal pathologies. However, the mouse placenta is structurally distinct from 
the human placenta, with differences in the vascularity, maternal-fetal inter-digitation, barrier 
interface, and blood flow [7, 34]. As previously stated, the human placenta is a discoid shape, 
contrasting the diffuse placenta of the pig or the zonary placenta of many carnivores. Unlike the 
human villous trees, which are bathed in maternal blood, the mouse placenta has a complex inter-
digitation, referred to as a labyrinth, where maternal and fetal vessels are placed in close proximity 
[7]. Additionally, while both are hemochorial, the human placenta is dichorial early during 
pregnancy, becoming monochorial later in gestation as the cytotrophoblast layer becomes sparse. 
In contrast, the mouse placenta is trichorial. Additional differences include the number of offspring 
per pregnancy. While humans and other primates tend to be singleton, many other animals such as 
mice, have litters of varying size. Along with the structural differences, the mouse placenta differs 
immunologically from the human placenta. To recapitulate the disease states observed in humans, 
high titers of virus are required, or ablation of the maternal IFN system using IFNAR knockout 
mice or IRF knockout mice [35, 36].  
Lastly, there are in vitro models, which can be utilized to study the placenta and infection 
during pregnancy, including explant studies, cell culture models, and “placenta-on-a-chip” 
systems. Villous trees collected from first, second, and third trimester can be dissected out and 
grown in extracellular matrix like substitutes, such as Matrigel [37]. These explant models have 
the benefit of maintaining the cellular composition and morphology of the villous trees, and can 
be used to determine specific cells susceptible to infection, as shown with T. gondii [38]. A range 
of human choriocarcinoma cell lines have been developed to study the placenta in vitro, such as 
BeWo, JEG-3, and JAR cells [39, 40]. These cells can be easily propagated, and are amenable to 
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genetic manipulations. However, some of the disadvantages to using these lines in that they reflect 
the carcinogenic cell origins, and are distinct from trophoblasts in a number of different ways. For 
example, they are polyploidy, and some of these lines do not produce many of the trophoblastic 
hormones mentioned above, and are morphologically distinct from trophoblasts, as the cell lines 
do not spontaneously form syncytium in culture [41-43]. The BeWo cells are able to form 
syncytium and produce hormones after exposure to forskolin or 8-bromo-cAMP, but 
pharmacological treatment can also affect other cellular processes [43-45]. Our lab has recently 
developed a system to model the syncytiotrophoblasts, utilizing a three dimensional co-culture 
system of JEG-3 cells, grown together with human brain microvascular endothelial cells 
(HBMEC), and recapitulate some of the morphology and secretory phenotype of the 
syncytiotrophoblasts, as well as recapitulating microbial resistance [46].   
In addition to immortalized cell lines, primary cells can be used for studying the placenta. 
Our lab and others have demonstrated that primary human trophoblasts, grown in culture for longer 
than 24 h differentiate, produce relevant hormones and form syncytium [47]. Our studies have 
focused on singleton third trimester placentas for culturing of trophoblasts. However, other groups 
have used first and second trimester trophoblasts, either cultured, or used in explant studies [38, 
48-50].  Lastly, placenta-on-a-chip models have recently been described as a system to study 
placenta barrier function and simulate transport across cellular layers. Some of the chips are made 
of Poly-dimethylsiloxane (PDMS) plates with microchannels that are seeded with 
choriocarcinoma cell lines, either JEG-3 or BeWo on the “maternal’ side, and endothelial cells on 
the “fetal” side, both attached to fibronectin-based ECM “basement-membrane” [51, 52]. 
However, these systems still have the disadvantages described for the trophoblast cell lines for 
infection studies.  
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1.1.2 Immunity during pregnancy 
Viviparity, growth and development of the fertilized egg inside the maternal body, creates the 
situation where the embryo and its related extraembryonic tissues, all expressing paternal or 
“foreign” antigens, are in contact with the maternal immune system. Hence, pregnancy is referred 
to as a semi-allograft. The maternal immune system is regulated throughout pregnancy to ensure 
that the adaptive immune response is not activated, ensuring tolerance of the fetus, and allowing 
for the remodeling of the maternal endometrium to facilitate placental development and function. 
The section below discusses key changes that occur in the maternal immune system, noting both 
the role of the maternal immune system to facilitate proper placental development and 
implantation, as well as the placental innate immune responses to infections.  
1.1.2.1 Adaptive immunity during pregnancy 
In response to the cycling estrous hormones, the uterine endometrial cells recruit leukocytes, 
through the production and secretion of different cytokines [53]. These leukocytes, including 
uterine natural killer (uNK) cells, macrophage, dendritic cells, and regulatory T cells, are important 
for ensuring proper implantation and placentation [54-56]. The majority of the decidua leukocytes 
are comprised of uNK cells [55, 57-59]. During the first trimester the uNK cells, dendritic cells, 
and macrophage begin to invade the decidua, interacting with extravillous trophoblasts [60, 61]. 
Furthermore, these immune cells are critical for proper invasion of the trophoblast cells, and 
deletion of these leukocytes has negative effects on implantation and fetal development [62-67]. 
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For instance, in the absence of uNK cells, decidual vascular remodeling and placental implantation 
are impaired [63, 68].  
An important component of maternal immune regulation and prevention of fetal rejection 
is the restricted expression of Human Leukocyte Antigens (HLA) by trophoblasts. The villous 
trophoblasts do not express any HLA-class I or class II antigens in vivo, though expression can be 
induced in vitro with inflammatory cytokines [69, 70]. As the extravillous trophoblasts 
differentiate, they begin to express HLA-E and HLA-G, which are important for suppressing the 
killing action of uNK cells, binding to the CD94/NKG2 receptor and immunoglobulin like receptor 
B1, respectively [71]. Importantly, while the class Ia HLA genes produce membrane bound 
proteins, the class Ib genes, such as HLA-G, produce membrane bound as well as soluble forms. 
This is the result of alternative splice variants [72]. While most class I HLA genes are regulated 
by enhancer sequences (enhancer A, interferon stimulated response element (ISRE), and class II 
major histocompatibility complex trans-activator (CIITA), these sequences are divergent in HLA-
G, rendering the protein unresponsive to NFκB, IRF-1, and CIITA [73-75].  
Another attribute of the maternal immune system during pregnancy is the ability of the 
maternal immunoglobulin to be transmitted passively to the fetus. Among the different 
immunoglobulins, only IgG is transferred across the placenta in significant quantities, with low 
level transfer during the first half of pregnancy, and a gradual increase until term [76]. The process 
is mediated by the neonatal FC receptor [77, 78]. Normally, the transfer of IgG is important for 
conferring immunity to the fetus, which has not yet fully developed its own adaptive immune 
response.  
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1.1.2.2 Innate immune responses of the placenta 
The trophoblasts are capable of recognizing a broad range of pathogens, expressing many pattern 
recognition receptors (PRR). These include Toll like receptors (TLR) 3, 7, 8, and 9 [79]. In addition 
to recognition, the trophoblasts produce many different anti-microbial peptides, such as beta 
defensins 1 and 3 [80, 81]. The cells can also produce secretory leukocyte protease inhibitor 
(SLPI), which has been shown to potently inhibit HIV infection [80, 82, 83]. Stimulation of 
trophoblasts choriocarcinoma cell lines, including JAR, BeWo, and JEG-3 with 
polyinosinic:polycytidylic (PIC) or infection with Sendai virus (SeV) has been shown to induce 
the production and release of type I interferons [79, 84]. Furthermore, we have demonstrated that 
trophoblast cell lines also potently induce type III interferons upon infection with SeV, or 
transfection with PIC (Figure 3-3D) [85]. 
1.2 INTERFERONS 
Interferons (IFNs) were discovered in the 1950s [86]. These proteins induce a signaling cascade 
that results in the up-regulation of a broad range of antiviral effector proteins, referred to as 
interferon stimulated genes (ISGs) [87]. Almost every mammalian cell type produces IFN in 
response to viral infection, in contrast to plants, insects, and lower chordates, which do not produce 
IFNs [88]. Different cell types produce specific IFNs, such as the production of IFNα by dendritic 
cells [89], or IFNκ by keratinocytes [90]. Since their initial discovery, three different types of 
interferons have been characterized. Type I and type III interferon will be discussed in detail 
below. IFNγ is the sole type II IFN. Activated T cells and NK cells produce IFNγ, and it signals 
through a distinct heterodimeric receptor. In most instances, IFNγ does not result in the induction 
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of a potently antiviral state, and is therefore outside the scope of this work, but has been reviewed 
by others [91]. These different types of IFN, along with their respective receptors and signaling 
pathways, are depicted in figure 1-2, below. In the following sections, we discuss the sensing of 
viral pathogens and induction of IFNs in cells, and review the IFN signaling pathway, leading to 
the induction of the antiviral effector proteins. We focus the last section on IFNλ, and how the type 
III interferons are distinct from the type I.  
 
Figure 1-2 - Different types of IFN. Depicted are the three classes of interferon molecules, their respective 
receptors, and signaling pathways. Type I interferon (green), predominantly made up of IFNα and IFNβ, 
signals through the IFNAR receptor heterodimer. This results in subsequent signaling through the JAK/STAT 
pathway, leading to the nuclear translocation of ISGf3 complex, comprised of STAT1, STAT2 and IRF9. The 
result of translocation of ISGf3 to the nucleus is the upregulation of hundreds of different ISGs. Type II 
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interferons (purple) are comprised of IFNγ, which is predominantly expressed by T cells in response to antigen 
presentation. Signaling through the IFNγ receptor, this pathway is distinct from the Type I and Type III IFN, 
in that it relies on cGAS nuclear translocation, and upregulates a subset of ISGs. Type III interferons (yellow), 
or IFNλ, signal through the IL-10R/IL-28AR heterodimer. The downstream signaling of IFNλ largely overlaps 
with the type I.  
1.2.1 Pattern Recognition/Interferon induction 
Upon microbial infections, the innate immune system detects pathogens using pathogen sensing 
molecules referred to as pathogen recognition receptors (PRR). These receptors recognize specific 
pathogen associated molecular patterns (PAMPS) that are well conserved amongst classes of 
pathogens [92]. Among the PRRs are the Toll-like receptors (TLRs), which are able to recognize 
a broad range of pathogens, including bacteria, viruses, fungi, and parasites, and also some host 
molecules that are indicators of pathogen caused damage to the cell, referred to as DAMPs (danger 
associated molecular patterns) [93]. Another group of cytosolic PRRs are the retinoic acid-induced 
gene like receptors (RLRs).  
The predominant TLRs involved in RNA virus sensing are TLR3 [94] and TLR7, which 
recognize dsRNA and ssRNA respectively. The cytosolic RNA-helicase domain containing 
protein RIG-I recognizes the distinctly negative ssRNA viral 5’-triphosphate containing RNA or 
short dsRNA. Melanoma differentiation-associated gene 5 (MDA5) recognizes longer dsRNA 
molecules. Binding of viral RNA to either MDA5 or RIG-I leads to association with mitochondrial 
antiviral signaling protein (MAVS). MAVS activation and dimerization results in the recruitment 
of adapter proteins that activate NFkB, IRF3 and IRF7. Upon dsRNA binding to TLR3, the 
receptors dimerize, and bring the Toll/Interleukin-1 receptor domain (TIR) in close proximity. This 
allows for the subsequent recruitment of adapter proteins, such as myeloid differentiation factor 
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88 (MYD88), TIR-domain-containing adaptor-inducing interferon B (TRIF), and TRIF-related 
adaptor molecule [95]. TRIF binding to TLR3 leads to the activation of IRF3, as well as NFkB 
and AP-1. TRIF recruits a number of different proteins including TNF receptor-associated factor 
3 (TRAF3) and TRAF6 [96, 97]. TRAF3 interacts with TRAF family member associated NFkB 
activator (TANK), which complexes with the kinases TANK-binding kinase 1 (TBK1) and IKKe. 
These two proteins phosphorylate IRF3, which then dimerizes, translocating to the nucleus to bind 
IFNβ enhancer sequences [98, 99]. Whereas the TLR3 receptor recognizes dsRNA, TLR7, upon 
recognition of ssRNA, dimerize and recruits MYD88, which then complexes with IL-1 receptor 
associated kinase 1 and 4 (IRAK1 and IRAK4), as well as with TRAF6. TRAF6 phosphorylation 
and activation leads to activation of NFkB and IRF7, which is bound to IRAK1 [100].  The above-
mentioned signaling cascades are depicted below, in figure 1-3.  
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Figure 1-3 - Pathogen recognition and IFN induction. RNA virus recognition by pattern recognition receptors 
(PRR) involved in the induction of IFN α and β. TLR7, present in the endosomal compartment of trophoblast 
cells, encounters ssRNA from viral infection or uptake of viral components from phagocytosis. Signaling from 
TLR7 through Myd88, complexes with IRAK1, IRAK4 and TRAF6 to activate IRF7. TLR3 is expressed in a 
wide range of cells types, and recognizes dsRNA, leading to the activation of TRIF, and then IRF3 through the 
IKK kinases and TBK1. Nuclear translocation of the interferon regulatory factors (IRF) leads to the induction 
of IFN.  
1.2.2 Type I interferons 
Type 1 Interferons, IFNβ and IFNα, are the most well studied interferons. Humans express 1 IFNβ, 
and 13 functional IFNα. These are defined based on their structural similarities. IFN ω, IFNε, and 
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IFNκ are more distantly related. IFNω is produced by leukocytes, and has properties that are very 
similar to IFNα. IFNκ expression is unique, in that it is only expressed in keratinocytes, and seems 
to be cell associated, only affecting the immediate surrounding cells [90, 101]. Studies using a 
murine model demonstrated that IFNε plays a specific role in the female reproductive tract, and is 
coordinated by the estrous cycle [102].  
1.2.2.1 IFNAR - Type I IFN Receptor 
The receptor for the Type I interferons belongs to the class II cytokine family receptors, and 
consists of relatively long intracytoplasmic domain (ICD), and relatively short intracytoplasmic 
domain [103]. These two subunits are termed IFNAR1 and IFNAR2. The ICD serves as a docking 
site for the tyrosine kinase, Janus kinase 1 (Jak1). Jak1 binds to sites on IFNAR2, while tyrosine 
kinase 1 (Tyk1) binds to sites on IFNAR1, in both instances, binding to the ICD adjacent to the 
transmembrane domain [104, 105]. As the ligand binds the receptor subunits, the proximity of 
each receptor and subsequently, the associated kinases, becomes closer, allowing for the auto and 
cross phosphorylation.  
1.2.2.2 JAK/STAT Pathway 
Phosphorylation of the IFNAR receptor, by the tyrosine kinases JAK and Tyk, produces multiple 
docking sites within the ICD, which can then be docked by the signal transducer and activator of 
transcription (STAT). Three different STAT proteins, STAT1, 2, and 3, have been demonstrated 
to bind the IFNAR complexes. STAT1 and STAT2 form a complex with IRF9, referred to as the 
ISGf3 complex. The ISGf3 complex, upon entering the nucleus, associates with the histone 
acetyltransferase CBP/p300, GCN5, and with the chromatin remodeling factor BRG1 [106-109]. 
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This complex enters the nucleus, binding to the DNA motif, interferon stimulated response element 
(ISRE), and enhancing the transcription of interferon stimulated genes (ISGs).  
1.2.2.3 Interferon stimulated genes (ISGs) 
Interferon stimulated genes are known for their role in inhibiting viral infection. To date, there are 
hundreds of ISGs that have been identified, though many have not yet been characterized for their 
direct role in inhibiting viral infection [87]. Additionally, ISGs have a diverse range of functions 
to inhibit viral infection, including interference with translation (PKR), degradation of RNA 
(OAS), or interference with viral assembly and release (Vipirin) [110]. Some viruses are sensitive 
to specific ISGs. For example, parainfluenza virus type 5 (PIV5) is sensitive to the ISG IFN-
induced protein with tetratricopeptide repeats 1 (IFIT1), but not to MxA, OAS, or PKR [111]. 
ISG15 functions to modify over a hundred different host proteins through ubiquitin like 
conjugation, referred to as ISGylation. Additionally, many of the genes involved in the IFN 
pathway, such as STAT1 and IRF9, are also upregulated, contributing to the positive feedback 
[112].  
1.2.2.4 Type I IFN in the placenta 
As was mentioned, choriocarcinoma trophoblast cell lines can respond to PRR agonists or viral 
infection by the induction of Type I interferons. Studies in this area, carried out in the 1980s and 
1990s, utilized infectivity assays and neutralization experiments to identify the presence of IFN 
[113, 114]. In some of these early studies, amniotic fluid or placental biopsies were collected, and 
tested for their ability to inhibit viral infections in vitro [115-118]. However, there were conflicting 
reports about the presence of IFNs in placentas and amniotic fluid in the absence of viral infection 
[119, 120]. Some studies suggesting the presence of IFN in amniotic fluid was derived from 
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amniotic cells were dismissed by other groups, contending that the IFN was actually derived from 
the placenta [121]. Other hurdles related to studying placental IFN included contamination of 
maternal blood, potentially masking the contribution of the placenta. Later studies addressed these 
concerns by using perfused term placentas from healthy mothers [122]. Interestingly, this group 
and others noted only moderate effects of anti-sera against IFNα and IFNβ [123], suggesting the 
presence of a then uncharacterized antiviral protein. Other reports supporting the production of 
IFN from the placenta, and possibly systemic effects during pregnancy, demonstrated that 
peripheral blood mononuclear cells (PBMCs) from healthy pregnant women showed an 
upregulation of many ISGs (ex. IFI44L, IFIT3, OAS1) [124], compared to the PBMCs from 
healthy non-pregnant women.  
1.2.3 Type III interferons 
In contrast to the type I interferons, which have been studied for over 60 years, the type III 
interferons, IFNλ1-4, were identified in 2003 [125, 126]. IFNλ4, a frameshift variant of IFNλ3 and 
thus considered a pseudogene, was reported in the last 5 years, identified largely based on genetic 
data [127]. Also belonging to the class II cytokine family, the type III IFNs are functionally similar 
to type I, resulting in the upregulation of ISGs. Structurally, they resemble the IL-10 family of 
cytokines [128], and there is no cross reactivity with the type I IFNs. The type III IFNs signal 
through a distinct heterodimeric receptor, IFNLR. The function and expression of IFNλ and 
IFNLR appear to be restricted to certain cell types, activating predominantly in epithelial and 
endothelial cells. This targeted signaling is in contrast to the ubiquitous nature of IFNβ. In this 
section we highlight the role of IFNλ in infections, and discuss the attributes that make the type III 
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distinct from the type I IFNs, particularly with regards to the expression in mucosal tissues and 
epithelial cells, as well as discussing differences in IFNλ4 expression in certain populations.   
1.2.3.1 Induction of IFNλ 
Type III IFNs are induced by the same mechanisms that lead to the induction of type I IFNs, as 
viral infections trigger PRR activation and signaling. One exception to this is the expression of 
IFNλ following activation of the cytosolic DNA sensor Ku70, which was demonstrated to be active 
in a broad range of cell types, which does not lead to induction of type I IFN [129]. The genetic 
locus of IFNλ is also distinct from IFNα/β. The genes encoding IFNα/β are located on chromosome 
9 in humans, whereas IFNλ1-4 are located on chromosome 19 [130]. The IFNλ promoter regions 
share similarities with the type I IFNs, containing binding elements for IRF-1, IRF-3, IRF-7, and 
NFκB [131, 132]. However, while IRF3, NFkB and AP-1 can lead to induction of IFNβ, IFNλ1 
can be activated by NFkB alone [133]. Additionally, IFNλ expression is regulated by the 
transcriptional repressor ZEB1 in epithelial cells [134].  
1.2.3.2 IFNλ signaling  
The type III IFNs are structurally more aligned with IL-10 cytokines based on crystal structure 
analysis, though the primary amino acid sequence closely resembles the type I IFNs. IFNλs signal 
through a distinct heterodimeric receptor, shown in figure 1-3. This structural and functional 
similarity with type I IFNs and IL-10 cytokines, such as IL-22, likely reflects a common 
evolutionary origin, protecting the epithelium from bacteria and viruses respectively [135]. The 
heterodimeric receptor contains one subunit is made up of the IL-10 family cytokine receptor IL-
10R. The other subunit is specific to IFNλ, referred to as IFNLR1. Despite similarities with other 
IL-10 cytokine family members, the receptor binding is unique to IFNλ [136]. 
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Downstream from receptor binding, the signaling of IFNλ overlaps with the type I IFN 
signaling, with activation of the JAK/STAT pathway, and subsequent ISGf3 nuclear translocation 
[125, 126, 137-139] and induction of hundreds of ISGs. However, despite the overlapping 
pathways, there appear to be differences in antiviral activity and in ISG induction [137, 140, 141]. 
These differences have been attributed to the magnitude of induction and the differences in the 
duration of the induction [142]. IFNα induction of an antiviral state is transient, lasting for 
approximately 6 hours. In contrast, IFNβ and IFNλ1-3 have longer lasting effects, with ISG 
expression sustained for 12-24 hours. The mechanism of for this difference in expression is not 
known, though it has been suggested that IFNα uniquely induces negative regulators [142]. This 
suggests that there are no uniquely expressed ISGs induced by IFNλ. Rather, the magnitude of 
expression is different, with IFNβ causing the most robust ISG induction, followed by IFNα, and 
then IFNλ 3, 1, and 2 (in that order). However, there may be specific promoter elements that 
distinguish the different IFNs and more a thorough comparison is required to further delineate 
them.  
1.2.3.3 Tissue expression of IFNλ 
Other than differences in the signaling and expression of ISGs, the effect of the type III IFNs is 
the most apparent in mucosal tissues and epithelial and endothelial cells, which are constantly 
exposed to commensal and pathogenic microbes [139, 143, 144]. Numerous studies have 
demonstrated the role of IFNλ in the respiratory tract, gastrointestinal tract, the liver, and the blood 
brain barrier. The IFNLR is expressed at high levels in human hepatocytes, and when infected with 
HCV or HBV, these cells produce IFNλ [145]. Other studies have demonstrated high levels of 
expression of IFNLR in gastrointestinal epithelial cells, with robust responsiveness to IFNλ [146]. 
In models where IFNLR was knocked out, such as in mouse airway or the intestinal epithelial 
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cells, viral pathogenesis was increased [134, 147]. IFNLR knockout mice also demonstrated 
increased sensitivity to West Nile virus (WNV), which might be related to the recently 
demonstrated role of IFNλ in maintaining the blood brain barrier integrity (BBB) [148].  
1.2.3.4 IFNλ polymorphisms  
Many humans have a functional IFNλ4. However, a single nucleotide polymorphism (SNPs), 
which causes a frameshift mutation, ablates production in populations encoding this mutation [127, 
149]. Interestingly, loss of IFNλ4 confers enhanced clearance of HCV infection, although the cause 
is unclear. IFNλ4 may potentially downregulate the expression of other IFNλ members. Another 
possibility is that high expression of IFNλ4 results in expression of negative regulators of the IFN 
pathway, rendering the cells less sensitive to future IFN stimulation [150]. Genome wide 
association studies revealed multiple IFNλ polymorphisms that are linked to improved clearance 
of viral infections, such as HCV, HBV, hCMV, and HSV-1 [151-155]. Other SNPs in the promoter 
region of IFNλ3 lead to higher expression, and better control of infections [156]. The mechanisms 
by which these polymorphisms affect IFNλ production and clinical responses remain unclear.  
1.3 MICROBIAL INFECTIONS DURING PREGNANCY 
Relatively few pathogens are capable of crossing the placental barrier, resulting in fetal infections. 
However, there are a number of viral, bacterial, or protozoan pathogens linked to pregnancy 
complications, resulting in severe maternal and/or fetal disease. Infection by these pathogens can 
lead to severe developmental abnormalities, morbidity and mortality [157] with some morbidity 
related to maternal immunological responses. In response to PIC, murine models as well as 
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trophoblast cell lines (HTR8) and primary trophoblasts produce proinflammatory cytokines, 
including TNFα, IFNγ, IL-12, and IL-6 [158]. These cytokines may activate the maternal immune 
response, which can lead to placental damage, miscarriage, fetal developmental or growth 
abnormalities, abortion, and spontaneous preterm birth [158]. There are also a number of different 
routes of infections, allowing the pathogens access to the fetus. In terms of viral infections, the 
mode of transmission is most frequently hematogenous. In this section, we highlight some of the 
different types of pathogens that have been linked to perinatal infections, discussing the basic 
biology of these pathogens, as well as pathways of maternal-fetal transmission. A more 
comprehensive list of pathogens associated with pregnancy complications and placental infections 
are presented in table 1.  
 
Table 1-1. Pathogens linked to placental/fetal infections 
Pathogens Type Tropisms 
Brucella spp. Bacteria Leukocytes, Epithelial cells[159] 
Coxiella burnetii Bacteria Leukocytes[160, 161] 
Listeria monocytogenes Bacteria Epithelial, Phagocytes[162] 
Mycobacterium tuberculosis Bacteria Leukocytes[163] 
Treponema pallidum Bacteria Unknown[164, 165] 
Leishmania spp.  Bacteria Leukocytes[166, 167] 
Plasmodium falciparum Parasite Erythrocytes, hepatocytes[168] 
Toxoplasma gondii Parasite All nucleated cells[169] 
Trypanosma spp. Parasite Epithelial, Endothelial[170] 
Cytomegalovirus Virus Leukocytes, trophoblasts[171, 172] 
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Lymphocytic choriomenigitis virus Virus Leukocytes[173, 174] 
Parvovirus B19 Virus Hematopoietic, endothelial[175, 176] 
Rubella virus Virus Broad[177] 
Varicella zoster virus Virus Leukocytes, neurons, epithelial[178] 
Herpes simplex virus Virus Leukocytes, neurons, epithelial [179, 180] 
   
1.3.1 Viral infections during pregnancy 
Viruses can gain access to the maternal-fetal compartment by a diverse range of routes, including 
infected sperm during fertilization, intrauterine infections occurring before or during the 
implantation process, hematogenous spread of the virus causing direct placental infection or 
transmission across the placenta, infected macrophages from the maternal blood supply crossing 
the placenta, infection resulting from a medical procedure such as amniocentesis, or infection of 
the fetus during the delivery process.  
1.3.1.1 Herpesviridae 
A number of members of the herpesviridae are connected with congenital infections and pregnancy 
complications, especially during primary infection. Broadly, the herpesviruses contain large linear 
dsDNA genomes packaged into a nucleocapsid core. Here we discuss three different herpesviruses: 
herpes simplex virus, cytomegalovirus, and Varicella Zoster virus, and the contribution they play 
towards perinatal infections.   
Herpes simplex virus 1 and 2 (HSV) can lead to pregnancy related disease either in utero, 
during delivery, or postnatally, resulting from breastfeeding. These viruses are members of the α-
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herpesvirus family, and are enveloped viruses with linear ds DNA genomes of approximately 152 
and 155 kb, respectively. There are approximately 1500 cases of neonatal infection from Herpes 
simplex virus each year in the United States [180]. Most of the infections occur perinatally from 
an infected maternal lower genital tract [179, 181]. Transplacental transmission is rare, and has 
been linked to fetal anomalies, including microcephaly, intracranial calcifications, and 
chorioretinitis. Using explant models, other groups have demonstrated that the 
syncytiotrophoblasts are resistant to HSV, but the underlying mesenchymal cells are permissive. 
However, these subjacent cells were only accessible following exposure of the explants to trypsin, 
which damages the trophoblast layer [182]. In contrast, extravillous trophoblasts may be more 
permissive to infection, and could explain poor placental attachment to the uterine wall during 
infection and subsequent miscarriage [182].   
Human Cytomegalovirus (hCMV) is one of the leading causes of severe prenatal viral 
infection. A member of the β-herpesvirus family, it is an enveloped dsDNA virus, with a genome 
of approximately 240 kb. For immune-competent individuals, hCMV usually manifests as a 
relatively benign disease. However, CMV can have severe consequences during pregnancy.  
Congenital CMV infection is not rare, although the risk associated with recurrent viral infection 
during pregnancy is low [183]. However, primary infection during pregnancy has a 30-40% risk 
of intrauterine transmission and clinical disease [184, 185]. Approximately 15% of women who 
acquire a primary infection early in their pregnancy have a spontaneous abortion [186]. During 
these instances, the placenta, but not the fetus, demonstrates signs of infection. Later during 
pregnancy, CMV infection can cause premature delivery or intrauterine growth restriction [187]. 
In instances where the virus is transmitted to the fetus, severe congenital defects can occur, such 
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as fetal growth restriction, cerebral ventriculomagly, microcephaly, intracranial calcifications, and 
chorioretinitis [188].  
Varicella zoster virus (VZV), the causative agent of chicken pox, is a highly contagious 
infectious agent, and a common childhood illness. However, infection of varicella during 
pregnancy is rare, since mothers are often immune to the virus by the time of childbearing age. 
VZV, like other herpes viruses, is a DNA virus, in which humans are the only host, and 
transmission occurs via the conjunctive and mucous membranes of the nasopharynx [189]. 
Generally, primary infection provides life long immunity. Herpes zoster infection during 
pregnancy, resulting from reactivation of the virus, has not been associated with congenital 
varicella syndrome, and incidence of vertical transmission is rare [190]. While not associated with 
first-trimester spontaneous abortion [191-193], vertical transmission may result in congenital 
varicella syndrome, where primary infection during the first two trimesters can result in range of 
devastating development abnormalities, including microcephaly, eye disorders like 
microphthalmia [178, 190, 194-196], or gastrointestinal abnormalities. Additionally, fetuses born 
with congenital varicella syndrome often present with hypertrophic skin scarring [178].  
1.3.1.2 Togaviridae 
The togaviridae are a family of enveloped simple single stranded RNA viruses. Originally named 
based on resemblance to roman cloaks in electron microscope micrographs, the togaviridae have 
a spherical virion structure [197]. This family of viruses includes many pathogens associated with 
human disease, and in particular a number of different viruses linked with perinatal infection. This 
section focuses on members of the two genera, rubivirus, and alphaviruses. In the genus rubivirus 
there is only a single virus, rubella, also known as German measles. In contrast to rubivirus, the 
alphavirus genus contains over 30 different viruses. These two are distinguished by genome 
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organization and nucleotide sequence. The togaviruses have non-structural replication proteins 
encoded by the 5’ end of the genome, and the structural proteins, making up the viral particles, 
encoded by the 3’ end. These structural proteins are encoded by a subgenomic mRNA.  
Rubella virus, the only member of the rubivirus genus, is a single stranded positive sense 
RNA virus, of approximately 9.7 kb. Currently, with the widespread vaccination against rubella, 
infection during pregnancy is rare. However, prior to vaccination, fetal infection during the first 
trimester had infection rates as high as 50%, with severe congenital defects associated with 
infection, including congenital rubella syndrome, characterized by deafness, CNS damage such as 
microcephaly, cardiac defects, and cataracts [198].  
The old world alphaviruses, which include Sindbis virus and Chikungunya virus, can cause 
acute febrile illness as well as more lasting arthrogenic diseases in humans, including myalgia and 
rash. The new world alphaviruses, including eastern equine encephalitis and Venezuelan equine 
encephalitis, are known to cause encephalitic disease. Among the alphaviruses, there is a link 
between gestational infection with Venezuelan equine encephalitis virus and spontaneous abortion 
[199].  
1.3.1.3 Human immunodeficiency virus 
Human immunodeficiency virus -1 is a member of the retroviridae. These viruses are characterized 
by the virion particles containing an RNA genome, and after entry into the host cell, the genome 
is reverse-transcribed into DNA. The transcribed viral genomic DNA is then integrated into the 
host chromosomal DNA. Through direct interaction between the viral envelope protein and the 
receptor CD4 and the chemokine receptor CCR5 or CXCR4, the virus targets cells of the immune 
system, causing suppressed immune systems [197]. HIV is the causative agent of AIDS, which 
currently affects 36.7 million people worldwide living with HIV. The World Health Organization 
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has estimated that there have been approximately 10 million babies born with Human 
immunodeficiency virus (HIV). While the rates of vertical transmission in developed nations have 
dropped significantly with the use of advanced anti-retroviral therapies, there is still a major burden 
in the most afflicted areas, such as sub-Saharan Africa. Interestingly, while most viruses linked to 
congenital pathologies infect the fetus predominantly in the first or second trimester, vertical 
transmission by HIV results mainly from invasive procedures during the pregnancy, or upon 
delivery [31]. In rare cases of fetal infection during pregnancy, it has been hypothesized that 
maternal immune cells, crossing into fetal circulation, transmit infection [200].  
1.3.1.4 Flaviridae  
The flaviridae comprises a family of single stranded positive sense RNA viruses. The genus 
contains over 50 viruses, most of which are arthropod-borne. In particular, two of the flaviviruses 
have been implicated in pregnancy complications, Dengue virus (DENV) and Zika virus (ZIKV). 
DENV, which is a major global health problem in tropical and subtropical areas, infects over 100 
million people each year, resulting in 25,000 deaths worldwide [201]. Dengue fever is caused by 
four different dengue virus serotypes, and is transmitted primarily by the mosquito Aedes aegypti, 
with Aedes albopictus as a secondary vector [202]. A retrospective study in West Guinea, where 
dengue is not endemic, found that infection during pregnancy resulted in an increase in premature 
births and preterm labor [203]. While there have been no reports about congenital infections and 
fetal malformations resulting from dengue infection during pregnancy, there is an increased risk 
of hemorrhage during delivery, with possible perinatal transmission at delivery [203-206].  
Unlike DENV, the recent ZIKV pandemic has demonstrated that ZIKV is strongly linked 
to congenital defects and developmental abnormalities. Zika virus was initially discovered in 
Uganda in 1947 [207]. For most infected individuals, the symptoms of ZIKV infection resemble 
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dengue fever, with acute febrile illness, headache, arthralgia, and rash. ZIKV infections tend to be 
less severe than DENV, with many individuals never developing symptoms. However, the recent 
pandemic in Brazil has demonstrated that infection with ZIKV during pregnancy is strongly linked 
with congenital malformations, most prominently microcephaly and fetal growth restriction. The 
Brazilian strain of ZIKV has been detected in the placenta, as well as in amniotic fluid and fetal 
brain, indicating the virus is capable of crossing the placental barrier [208, 209]. However, it 
remains unclear how this virus gains access to the fetus. Recent studies have demonstrated that 
ZIKV infects primary placental cells, including cytotrophoblasts, endothelial cells, fibroblasts, 
Hofbauer cells from chorionic villi, and amniotic epithelial cells [48]. However, that same study 
also demonstrated that the syncytiotrophoblasts from first trimester placental explants were not 
infected. We have recently published work (see below) further supporting these findings, as 
syncytiotrophoblasts from term placentas were refractory to ZIKV [85].  
1.3.2 Protozoan infections during pregnancy 
Perinatal parasite infection can also lead to severe consequences for the developing fetus. Of 
particular relevance is the protozoan parasite Toxoplasma gondii. This intracellular parasite is able 
to infect almost all nucleated cell types [169]. Contraction of Toxoplasma can occur from ingestion 
of uncooked meats, contaminated foods, or transmission of the oocysts from infected cat feces. 
Infection with T. gondii during pregnancy can result in congenital toxoplasmosis, leading to 
neurological disorders, blindness, or even miscarriage or stillbirth [210]. Severity of the infection 
is dependent on the stage of pregnancy. Maternal infection during the first trimester often results 
in miscarriages, while infection during the second trimester results in blindness, microcephaly, or 
other cognitive disabilities. The risk of vertical transmission usually occurs during a primary 
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infection [211]. Using first trimester villous explants, it has previously demonstrated that EVTs 
are preferentially colonized by the parasite, relative to the more resistant syncytiotrophoblasts [38].  
Malaria, endemic in 103 countries, is estimated to affect between 300-500 million people 
each year [212]. Caused by plasmodium falciparum (P. vivax, P. ovale and P. malariae cause less 
severe disease) studies have suggested that infants surviving a placental malaria infection can 
suffer adverse neurodevelopment sequelae and have abnormal responses to parasite infections later 
in life [213]. In these instances, the adverse effect on fetal development is attributed to the 
inflammatory response in the placenta, and the parasite itself [214].  
1.3.3 Bacterial infections during pregnancy 
A comprehensive list of bacterial pathogens linked to congenital defects is presented in Table 1. 
Here, we highlight one of those bacteria, Listeria monocytogenes, which is a ubiquitous bacterial 
pathogen that often causes food borne illness in humans and many other animals. Healthy adults 
frequently ingest L. monocytogenes. In pregnant women, L. monocytogenes can spread to the feto-
placental unit, resulting in spontaneous abortion, stillbirth or preterm labor, depending on the stage 
of pregnancy [215-217]. Other groups have demonstrated that the syncytiotrophoblasts are 
resistant to infection by L. monocytogenes, and that the extravillous trophoblasts are the 
predominant site of infection [218]. They suggest that this resistance is the result of the 
syncytiotrophoblasts lack of E-cadherin, limiting the entry of the bacterium.  
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1.4 MICRORNAS 
In recent years the appreciation for ncRNA has grown tremendously, as we now understand that 
many of these non-protein coding RNAs are crucial for maintaining proper balance and 
homeostasis. A major class of these ncRNAs is the small regulatory RNAs known as microRNAs 
(miRNA). These miRNAs were first identified in the Caenorhabditis elegans, by Lee et al [219] 
and by Wightman et al., [220]. These initial studies were of the gene lin-4, which does not produce 
a functional gene product, but rather a small 22 nt transcript which targets the 3’ untranslated 
region (UTR) of lin-14. Within these 3’ UTRs are conserved elements that are complimentary to 
the lin-4 transcript. Since their initial characterization, miRNAs have been identified in a broad 
range of genomes, including protists, plants, animals and viruses. These small ncRNAs are 
approximately 20-24 base pairs in length. Functionally, miRNAs act to prevent translation of 
mRNA transcripts through a block in translation or by degradation of the transcript. This process 
is completed through the RNA-induced silencing complex (RISC), a complex of proteins including 
Argonaute (Ago), which guides the miRNA to the corresponding mRNA, binding through an 
imperfect match in the base pairs, discussed further below. The degree to which miRNAs inhibit 
protein expression is often modest [221, 222]. However, disruption of miRNA expression levels 
can have profound biological consequences. There is a growing list of miRNAs implicated in 
human disease, including cancer, heart disease, kidney disease, and psychiatric disorders [223-
227].  
The expression profile for miRNAs in different tissues is highly variable, and dependent 
upon developmental and pathological states. Within the human placenta there is a distinct 
repertoire of miRNAs, with the majority belonging to the two largest miRNA clusters in the human 
genome. The first is the chromosome 14 miRNA cluster, and the second is the chromosome 19 
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miRNA cluster. In this section, we focus on the biogenesis of miRNAs, the machinery involved in 
regulation of gene expression by miRNAs, and the specific attributes and relevance of the C19MC 
miRNAs as they relate to pregnancy, focusing on their role in the placenta and contributions to 
protecting the fetus from viral infections.   
1.4.1 MiRNA biogenesis 
Encoded by the genome, miRNAs are initially transcribed by RNA-Pol II as long primary miRNA 
transcripts, termed pri-miRNAs [228]. This primary transcript, derived from either mRNA or 
intronic sequences, then undergoes a number of processing steps before becoming a mature and 
functional miRNA. The primary structure contains self-complementary regions, allowing for 
folding back on itself to become a hairpin, ranging between 65-80 nucleotides in length. This 
primary sequence then undergoes endonucleolytic cleavage by the microprocessor, a complex 
consisting of the RNAse III endonuclease Drosha, guided by the RNA binding protein (RBP) 
DGCR [229, 230]. Following this processing step, the hairpin stem loop precursor, now referred 
to as a pre-miRNA, is exported out of the nucleus by the RanGTPase-dependent exportin 5. Once 
in the cytoplasm, the pre-miRNA is further cleaved by another RNAse III endonuclease, known 
as Dicer, in conjunction with the RBP TPBP [231-234]. Following this cleavage step, the mature 
20-24 nt duplex is loaded onto the RISC effector protein complex [235-237]. The process of 
miRNA biogenesis is depicted in figure 1-4, below.  
Once the mature duplex is loaded onto the RISC complex, it is unwound by the helicase 
activity, and the guide strand (the strand with the lowest internal stability at the 5’ end) is retained 
to form the active RISC complex, while the other passenger strand is discarded [238, 239]. These 
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canonical pathways for miRNA biogenesis and RISC complex formation and function are the most 
common in mammalian cells, though other pathways have recently been described.  
 
 
Figure 1-4 - miRNA biogenesis. In the canonical miRNA biogenesis pathway, miRNAs are initially transcribed 
from intronic, exonic, or intergenic sequences. Following transcription by Pol II, the primary miRNA is then 
bound by the RNA binding protein DGCR8 and cleaved by the RNAse III Drosha. Following this, the pre-
miRNA, at this point ranging from 55-70nt, is then exported from the nucleus by exportin-5, where Dicer 
processes it. The mature miRNAs are then loaded onto the RNA induced silencing complex, where they bind 
the seed sequence of the complementary 3’UTR of the target mRNA. (From Mouillet et al., 2015 [240]; 
modified, with permission, from Elsevier 2015.) 
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1.4.2 Placental specific miRNAs 
With its inherent transcriptional complexity, it is not surprising that the placenta expresses a broad 
range of miRNAs, with a subset of these being specific to the trophoblasts [241-245]. Thus, 
understanding the role of these placental specific miRNAs has been challenging. Murine models 
that lack either Dicer or Ago2 are embryonic lethal [246-248]. Mir-675, expressed exclusively 
from the placentally-abundant H19 transcript [249], demonstrated elevated expression levels 
during the second half of gestation. This expression has been correlated with reduced growth, as 
mir-675 appears to inhibit placental cell proliferation, likely due to the silencing of insulin like 
growth factor receptor 1 [249].  
To date, our understanding of the functional significance of many of placental miRNAs is 
severely limited. For instance, murine models that lack the C14MC cluster (containing 77 mature 
miRNAs), which is abundant in the placenta, do not exhibit any phenotypic differences. Some of 
the best studied miRNAs in the placenta, mir-17~92 cluster, have been shown to play a role in 
tumorigenesis [250] and specific members from this cluster have been shown to regulate the 
differentiation of trophoblast cells, targeting specific proteins such as CYP19A1 (aromatase) and 
transcription factor GCM1 which play a pivotal role in syncytium formation [251]. However, a 
targeted deletion of these miRNAs in the murine model did not generate an obvious phenotype 
[252]. Computational analysis has indicated a role for a few miRNAs within the placenta, and 
these have subsequently been validated experimentally. For instance, mir-378-5p and mir-376c 
were demonstrated to enhance trophoblast proliferation and invasion, through the targeting of the 
nodal pathway [253, 254]. In contrast, mir-155 inhibits trophoblast invasion, targeting CYR61 and 
Cyclin D1, potentially contributing to the development of preeclampsia [255, 256]. Other miRNA 
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species such as mir-210 and mir125b-1-3p, were implicated in the impairment of trophoblast 
proliferation and invasion, thereby contributing to placental disorders [257-260].  
1.4.2.1 C19MC 
Our lab has a focused on the chromosome 19-miRNA cluster (C19MC), which is the largest 
miRNA cluster in the human genome, and is nearly exclusively expressed in the placenta of 
humans and primates, with no murine ortholog [261]. This is the result of primate specific 
evolutionary expansion, potentially due to Alu-mediated rearrangements of the C19MC [262]. 
Spanning 100kb, this cluster of miRNAs contains 46 intronic miRNA genes, and produces 58 
mature miRNAs [261]. The C19MCs are extraordinarily enriched for repetitive Alu sequences, a 
class of short interspersed nuclear elements (SINE), each approximately 300 nt long of highly 
repetitive DNA [263].  This cluster is highly expressed in the syncytiotrophoblasts, as well as other 
trophoblast cell lines. 
The C19MC miRNAs are also expressed in human embryonic stem cells, and that 
expression declines upon differentiation [264-266]. The expression of C19MC miRNA in the 
extravillous trophoblasts is markedly lower in comparison to the villous trophoblasts [267]. 
Further, overexpression of the C19MC in extravillous trophoblasts reduces cell migration in vitro. 
While expression of the C19MCs in healthy individuals is limited to expression in the trophoblasts, 
aberrant expression of these miRNAs has been demonstrated in a number of different malignancies 
[268-274].  
1.4.2.2 C19MCs: A role in autophagy 
An unexpected role of the C19MCs is their involvement in viral resistance. The C19MCs, which 
are expressed in particularly high levels in primary human trophoblasts, are capable of conferring 
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resistance to a diverse panel of DNA and RNA viruses [275]. Through exosome-mediated delivery, 
the C19MC miRNAs were determined to induce autophagy in recipient non-placental cells, 
thereby conferring viral resistance. 
Autophagy is an evolutionarily conserved catabolic process, in which cells maintain 
homeostasis by sequestering aged, damaged, or ubiquitylated proteins into double membraned 
vesicles, known as autophagosomes. The autophagosome cargo is then digested upon fusion of the 
vesicle with the lysosome. Autophagy is initiated during periods of cellular stress, such as 
starvation and nutrient deprivation, or in response to the cellular stress of viral infection. There are 
a number of viruses, which can lead to congenital infections, including CMV [276], VZV [277], 
B19V [278], and ZIKV [279], and are known to induce autophagy. Autophagy has been shown to 
be both antiviral and proviral in a number of different studies [280]. In cases where autophagy is 
antiviral, cytoplasmic viruses can be sequestered by the autophagosome and degraded upon fusion 
with the lysosome, potentially leading to the viral components activating innate immune pattern 
recognition receptors. This is the case with sindbis virus and VSV [281, 282]. However, certain 
viruses have evolved mechanisms to antagonize the autophagic machinery, such as HSV and 
hCMV [283, 284]. For other viruses, autophagy is beneficial, as is the case with VZV and dengue 
[285].  
1.4.2.3 Extracellular vesicles released by trophoblasts 
It has recently become clear that miRNAs not only function in the cells producing them, but are 
capable of being released by the cells and taken up by distant recipient cells, broadening their role 
to cell-cell communications [286, 287]. This miRNA based cell-cell communication is important 
for maintaining homeostasis, tissue physiology and certain disease states [288-290]. This can be 
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observed in the release of individual protein bound miRNAs, but also in the packaging of miRNAs 
into extracellular vesicles such as exosomes [291-294].  
The syncytiotrophoblasts, like other epithelial cells, release a variety of extracellular 
vesicles into the maternal circulation. Among these are the apoptotic blebs, microvesicles, and 
exosomes [295-298]. The largest of these vesicles, the apoptotic bodies (AB), range from 1-5 µm, 
and are produced by shedding of trophoblast at baseline with an increase of fragments during 
apoptosis [299]. The microvesicles are smaller than the AB, ranging between 200 nm and 1 µm. 
These vesicles are the result of budding from the plasma membrane [298]. The exosomes are 
produced from invagination of the microvesicular body (MVB), which then fuses with the plasma 
membrane releasing its cargo of exosomes into the circulation [290, 300]. The exosomes range in 
size between 40-150 nm, and as our group has previously reported, contain miRNAs from the 
C19MC family [301]. Exosomes, known to be involved in cell-cell communication [292], are 
involved in immune signals [302, 303]. These trophoblast exosomes may be involved in immune 
tolerance, potentially through the reduction in NK cell receptor NKG2D expression, Fas ligand 
mediated apoptosis, or tumor necrosis factor (TNF)-related ligand inducing apoptosis [245, 302, 
304]. In particular, our lab has delineated the role of exosomes in conferring viral resistance to 
non-placental recipient cells [275].  
1.5 SPECIFIC AIMS 
Given the severe consequences of primary infection during pregnancy and risk of subsequent 
fetal infection and disease, understanding the mechanism by which the placenta limits fetal 
infection by viruses is crucial for designing treatment strategies and therapeutics. Many groups 
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have demonstrated, using explant models, that the placenta can actively limit infection by a 
number of different pathogens such as protozoan parasites, bacterial infections, and viral 
infections. In many of these studies, it was demonstrated that the syncytiotrophoblasts were highly 
resistant to infection, but that the underlying cytotrophoblasts and adjacent extravillous 
trophoblasts were permissive [38, 48, 305].  However, the mechanisms of syncytiotrophoblasts’ 
resistance to infection are not fully understood. Additionally, while previous groups demonstrated 
that in response to PRR agonists or in response to infection trophoblast explants could produce 
type I interferon, the protective function of syncytiotrophoblasts in the absence of infection was 
not known [80, 117]. Therefore, we set out to elucidate the underlying mechanisms by which 
syncytiotrophoblasts were resistant to viral infection, as well as the mechanisms by which the 
trophoblasts were able to confer resistance to non-trophoblast recipient cells. Previous work from 
out lab, using primary human trophoblasts, identified high levels of basal autophagy in the PHT 
cells as one such mechanism of viral-resistance. This work also demonstrated that this resistance 
could be conferred to other cells through exosomal mediated delivery of the C19MC miRNAs, and 
subsequent induction of autophagy. We hypothesize that PHT cells utilized additional 
mechanisms of viral resistance, which could also be conferred to non-placental cells, and 
that this resistance was active against a number of pathogens associated with perinatal 
infections. Identifying the different antiviral pathways deployed by the primary human 
trophoblasts and how they can inhibit microbial infection in the placenta and surrounding tissues 
may lead to the development of new treatment and prevention strategies for perinatal infections. 
 
Aim 1) Characterize the effects of the C19MC microRNAs on pathogens associated with 
intrauterine infections Rationale: Our lab previously found that non-placental cells exposed to 
CM were resistant to the majority of viruses screened. Here we address a broader panel that 
includes microbial pathogens linked to congenital syndromes and perinatal infections. 
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Aim 2) Identify additional antiviral pathways utilized by primary human trophoblasts 
Rationale: We observed differences in the degree of antiviral activity between conditioned 
medium from PHT cells and the C19MC miRNA mimics.  
 
Aim 3) Elucidate the differences among PHT derived extracellular vesicles, focusing on 
antiviral effects Rationale: We previously reported that exosomes derived from PHT cells are 
able to confer viral resistance to non-placental recipient cells. Here we expand these finding to 
examine additional extracellular vesicles derived from PHT cells and their functional significance.  
 
Understanding how the placenta is able to limit fetal infection and how this process is 
regulated is important for developing treatments and therapies for a broad range of highly relevant 
diseases. This research will elucidate some of the mechanisms involved in defense at the 
maternal-fetal interface.  
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2.0  HUMAN TROPHOBLASTS CONFER RESISTANCE TO VIRUSES 
IMPLICATED IN PERINATAL INFECTIONS1 
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PhD; Derek W. Trobaugh, PhD; William B. Klimstra, PhD; Lori A. Emert-Sedlak, PhD; Thomas 
E. Smithgall, PhD; Paul R. Kinchington, PhD; Stephen Vadia, PhD; Stephanie Seveau, PhD; Jon 
P. Boyle, PhD; Carolyn B. Coyne, PhD; Yoel Sadovsky, MD 
 
Data for figure 2-1A was contributed by Teryl Frey and Christie Sleigher. Data for figure 2-1B 
and 2-1C was partially contributed by Derek Trobaugh and William Klimstra. Data for figure 2-5 
was contributed by Stephanie Seveau.  
2.1 INTRODUCTION 
Beyond providing a physical barrier between the maternal and fetal vasculature, the placenta 
governs the exchange of gases, nutrients, and waste products between these two compartments. In 
the hemochorial placenta, this exchange is regulated primarily by the syncytiotrophoblasts, a layer 
of multinucleated, terminally differentiated cells that are bathed in the maternal blood and play a 
critical role in protecting the developing fetus from invading pathogens [5]. Despite this defensive 
barrier, some pathogens are able to invade the fetal environment.  
                                                 
1 Reprinted with permission from the American Journal of Obstetrics and Gynecology 
 43 
Viral infection of the intrauterine compartment can spread to the fetus and/or the mother. 
Active maternal viral infections can lead to infection during delivery or to pregnancy loss (either 
early or late) resulting from systemic spread of the infection [4]. Viruses that are transmitted 
directly to the fetus can result in developmental abnormalities or fetal or neonatal disease. For 
example, prior to the widespread use of vaccination, fetal infection rates by the rubella virus were 
nearly 50% during maternal rubella infection in the first trimester of pregnancy and were 
associated with congenital rubella syndrome, characterized by deafness, cataracts, damage to the 
central nervous system, and cardiac defects [198]. Congenital infection with varicella during 
pregnancy can lead to spontaneous abortion or neonatal varicella infection, which may result in 
devastating birth defects known as congenital varicella syndrome [178, 190]. Venezuelan equine 
encephalitis virus has been linked to pregnancy complications such as spontaneous abortion [199]. 
HIV tends to be transmitted during vaginal delivery or invasive procedures [31].  
Beyond the formation of a syncytial physical barrier, mechanisms by which placental 
trophoblasts influence viral infections are insufficiently understood. We recently demonstrated 
that primary human trophoblasts (PHT) are resistant to infection by an unrelated panel of viruses 
[275]. Furthermore, viral resistance was conferred to non-trophoblast cells when incubated with 
conditioned medium from PHT cells. This resistance was mediated, at least in part, by exosomal 
delivery of miRNAs from the chromosome 19 microRNA cluster (C19MC), which is the largest 
miRNA cluster in humans unique to primates and almost exclusively expressed in the placenta 
[263]. C19MC miRNAs are highly expressed in exosomes released from PHT cells, and can be 
found circulating in the plasma of pregnant women [245, 301]. In cells exposed to PHT- 
conditioned medium we also observed a strong induction of autophagy, a pro-survival catabolic 
process where cellular organelles are partly or fully enclosed in cytoplasmic phagosomes, and 
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degraded upon fusion with the lysosomes. Autophagy was also observed in cells transfected with 
selected miRNA members of the C19MC, and attenuation of autophagy mitigated this antiviral 
effect [275]. Here we expand upon our previous observations and focus on viruses that are 
pertinent to fetal infection during pregnancy and/or delivery, including rubella virus and other 
togaviruses, HIV, and varicella zoster virus (VZV). Additionally, we compared these effects to 
infection by two clinically relevant non-viral perinatal pathogens, Listeria monocytogenes, and 
Toxoplasma gondii.  
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2.2 RESULTS 
2.2.1 PHT conditioned medium or miRNA mimics from the C19MC attenuate infection of 
select members of the Togaviridae family 
We found that, when compared to non-conditioned medium, pre-exposure to PHT conditioned 
medium markedly reduced the infection of Vero cells by rubella virus (Fig. 2.1A)2. We expanded 
our studies to other members of the Togaviridae family and measured the activity of luciferase 
from reporter viruses to represent the relative infection of a panel of viruses from the alphavirus 
genus [306]. We found that infection by EEEV, VEEV, CHIKV, and SINV was attenuated in cells 
exposed to conditioned medium (Fig. 2.1B)3. Because we had previously shown that PHT-
conditioned medium contained relatively high levels of antiviral C19MC miRNAs [275], we tested 
the antiviral activity of one of these miRNAs, miR-517-3p, shown previously to confer resistance 
to VSV, VV, and herpes simplex virus-1 (HSV-1). Indeed, we found that transfection of a miR-
517-3p mimic significantly reduced infection of only CHIKV and SINV when compared to cells 
transfected with a scramble control miRNA (Fig. 2.1C).  
                                                 
2 Data related to rubella plaque assays was provided by Dr. Teryl Frey (Georgia State 
University, Atlanta GA) 
3 Data related to alphavirus infectivity assays was contributed to by Dr. Derek Trobaugh 
(University of Pittsburgh, Pittsburgh PA) 
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Figure 2-1 - PHT-conditioned medium or miRNA mimics from Chromosome 19 miRNA cluster attenuate 
infection of select togaviruses. (A) Log scale of Rubella virus titers from cells exposed to non-conditioned or 
conditioned PHT medium. Data are mean of three independent plaque assays, each run in duplicate. p <0.05 
(Student’s t test). Data related to figure 2-1A provided by Dr. Teryl Frey (Georgia State University, Atlanta 
GA) (B) Activity of alphavirus luciferase reporter constructs. Eastern equine encephalitis virus (EEEV), 
Venezuelan equine encephalitis virus (VEEV), Chikungunya virus (CHIKV), and Sindbis virus (SINV), 
expressing luciferase in Vero cells, were exposed to conditioned PHT or control non-conditioned medium. Data 
are presented as percent infection relative to control and represent a mean of three independent infections, 
each run in triplicate. p <0.0001 (ANOVA with Bonferroni correction). (C) EEEV, VEEV, CHIKV, and SINV 
luciferase expression in cells transfected with miR-517-3p or control scrambled mimic. Data are presented as 
percent infection relative to control and represent a mean of three independent infections, each run in triplicate. 
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p <0.0001 (ANOVA with Bonferroni correction). Data related to figure 2-1A and 2-1B partially contributed by 
Dr. Derek Trobaugh (University of Pittsburgh, Pittsburgh PA) 
 
 
2.2.2 PHT-conditioned medium attenuates HIV-1 infection  
To determine whether conditioned PHT medium could inhibit HIV-1 infection in non-
trophoblastic cells, we used an HIV-1 infectivity assay, described in the materials and methods. 
We observed a significant reduction in Tat-induced luciferase expression in cells that were exposed 
to conditioned medium compared to cells exposed to non-conditioned medium (Fig. 2.2A). To 
investigate whether or not miR-517-3p was capable of conferring resistance to HIV-1, we 
transfected TZM-bl cells with scramble control miRNA, miR-517-3p, or miR-720, a non-C19MC 
miRNA expressed in trophoblasts. We observed a non-significant trend in reduction of HIV-1 
reporter activity in cells transfected with miR-517-3p, but not with miR-720 (Fig. 2.2B).  
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Figure 2-2 - PHT - conditioned medium inhibits HIV infection. (A) Relative luciferase activity (RLU) of an HIV 
Tat-inducible reporter in TZM-bl cells exposed to either conditioned PHT or control non-conditioned medium 
and infected with increasing concentrations of HIV, as described in Methods. Data are representative of three 
experiments, each performed in triplicate. * denotes p <0.05, and ** denotes p <0.001 (Student’s t test). (B) 
Relative luciferase expression in TZM-bl cells transfected with miR-517-3p, miR-720, or control scrambled 
mimic and infected with increasing concentrations of HIV. Data are representative of three experiments, each 
performed in triplicate. None of the differences were statistically significant.  
 
2.2.3 PHT conditioned medium or C19MC miRNA mimics attenuate VZV replication  
Using either a VZV reporter virus that expresses luciferase after an immediate early varicella gene 
(ORF63) or a reporter virus expressing luciferase after a late VZV gene (ORF9), we found that 
pre-exposure to PHT conditioned medium only impacted the late viral gene reporter, but did not 
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significantly impact expression of the immediate early viral reporter (Fig. 4A). We next assessed 
the effect of miR-517-3p on VZV infection.  Because of inefficient transfection of HFF cells with 
miRNA mimics, we transfected VZV permissive MeWo cells [307] with miR-517-3p, miR-720 
(non-C19MC control), or scrambled miRNA mimics. We found that transfection of miR-517-3p, 
but not the control miRNAs, significantly reduced luciferase activity due to infection with 
VZVORF9 (Fig. 4B), albeit to a lesser extent than PHT conditioned medium.  
 
Figure 2-3 - PHT-conditioned medium and miRNA mimics from chromosome 19 miRNA cluster attenuate 
VZV. (A) Relative luciferase activity (RLU) from cells infected with either immediate early (IE) reporter virus, 
or “late” ORF9 reporter virus, exposed to either non-conditioned or conditioned PHT medium. Data are 
representative of three independent experiments, each performed in triplicate. p <0.001 (Student’s t test. (B) 
Relative luciferase activity (RLU) in MeWo cells transfected with either miR-517-3p, miR-720, or scrambled 
mimic and infected with VZV_ORF9_Luc. Data are representative of three independent experiments, each 
performed in triplicate. p <0.05 (ANOVA with Bonferroni correction).  
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2.2.4 PHT conditioned medium has no effect on infection by the non-viral perinatal 
pathogens Toxoplasma gondii or Listeria monocytogenes 
To determine whether conditioned PHT medium could inhibit T. gondii infection, we 
exposed HFF cells to either PHT conditioned or non-conditioned medium for 24 h and determined 
infection by YFP-expressing T. gondii [308]. We found that PHT conditioned medium had no 
effect on T. gondii infection (Fig. 5A) quantified by vacuole number and size (Fig. 5B-C). We next 
tested whether PHT conditioned medium could confer resistance to L. monocytogenes in Caco-2 
cells. Bacterial burden was measured after 1.5, 5, and 10 h time points. Our results showed a lack 
of consistent reduction in L. monocytogenes burden (Fig. 6)4. 
                                                 
4 Data related to L. monocytogenes assays was provided by Dr. Stephanie Seveau (Ohio 
State University, Columbus OH) 
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Figure 2-4 - PHT-conditioned medium has no effect on Toxoplasma gondii infection. (A) Representative 
micrographs showing fluorescent parasites within vacuoles in U2OS cells exposed to non-conditioned or 
conditioned PHT media. Arrow denotes parasitophorous vacuole. Scale bar =10 μM. (B) Vacuole number, or 
(C) vacuole size in cells exposed to conditioned or non-conditioned media. Quantities are the average of four 
fields per sample and were assessed via three independent experiments. None of the differences were 
statistically significant.  
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Figure 2-5 -Primary human trophoblast conditioned medium has no effect on Listeria Monocytogenes 
replication. Colony forming units for L. monocytogenes after infection of 1.5, 5, and 10 h, as detailed in Methods. 
Data are presented as percent replication of bacteria in cells exposed to conditioned medium compared to that 
of bacteria in cells exposed to non-conditioned medium. Data presented are the mean of three independent 
experiments. None of the differences were statistically significant. Data provided by Dr. Stephanie Seveau (Ohio 
State University, Columbus OH) 
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2.3 DISCUSSION/COMMENT 
2.3.1 Study Design 
 
Figure 2-6 - Experimental design and Model. (A) Primary human trophoblasts (PHT cells) were collected from 
healthy singleton term placentas, and cultured for 48-72 hours. The conditioned medium from these cells was 
then transferred to non-trophoblast recipient cells and incubated for 24 h prior to infection. Infectivity assays 
were then performed to quantify relative pathogen infection between control non-conditioned and conditioned 
medium. (B) Proposed model of transmission for C19MC miRNAs packaged into exosomes. Exosomes are 
transferred from the placenta into maternal circulation (M), and can lead to subsequent inhibition of viral 
infection. It is unclear exosomes are transferred to the fetus in biologically meaningful amounts (F).   
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2.3.2 Principle findings and their meaning 
We recently demonstrated that PHT cells are resistant to a diverse panel of viruses, including 
coxsackie virus B, poliovirus, VSV, vaccinia virus, HSV-1, and cytomegalovirus. Importantly, we 
found that this resistance could be conferred to non-trophoblast cells by exposing them to PHT 
conditioned medium and, to a lesser degree, to C19MC miRNAs [275]. Here we expanded our 
experiments to include viruses that are associated with human perinatal infection and to assess the 
effect of PHT conditioned medium on non-viral pathogens [5, 309]. We first tested rubella, a 
togavirus that crosses the placenta by hematogenous dissemination and causes congenital rubella 
syndrome [198]. We then broadened our studies to include other members of the togavirus family. 
The Old world alphaviruses, including CHIKV and SINV, cause febrile and arthritogenic disease 
in humans, while the New world alphaviruses, including EEEV and VEEV, can cause acute 
encephalitis in humans [310-312]. Infection by all four alphaviruses was significantly attenuated 
in cells pre-exposed to PHT conditioned medium. Interestingly, transfecting cells with miR-517-
3p attenuated infection by the Old world, but not the New world, alphaviruses. 
We also found that PHT conditioned medium attenuates infection by HIV-1, which is 
transmitted to the fetus predominantly during delivery [30], with less frequent antenatal 
transmission during invasive procedures such as amniocentesis [313]. In addition, we found that 
pre-exposure to PHT conditioned medium significantly reduced cell infection by VZV, the 
causative agent of chickenpox and a significant perinatal pathogen which causes the rare but 
devastating congenital varicella syndrome [314]. VZV gene expression occurs in a cascade, with 
immediate-early, early, and late viral genes being expressed in sequence. Interestingly, our data 
suggest that the effect of PHT conditioned medium is observed only on late viral genes during 
VZV infection. We previously observed inhibition of early gene expression in other large DNA 
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genome viruses, vaccinia virus and HSV-1, suggesting that the underlying mechanism of inhibition 
may depend on the viral life cycle and on the timing of infection during pregnancy. 
We found no effect of PHT conditioned medium on infection by the protozoan Toxoplasma 
gondii, which is an important perinatal pathogen, that causes direct fetal organ damage.[315] 
Similarly, PHT conditioned medium had no consistent effect on infection by L. monocytogenes, a 
Gram-positive facultative intracellular pathogen that can cause miscarriage, stillbirth, or neonatal 
meningioencephalitis [316]. As syncytiotrophoblasts were previously shown to be resistant to 
colonization by T. gondii or by L. monocytogenes,[38, 218] our findings may indicate that PHT-
conditioned medium induces a primarily antiviral state, while other mechanisms may drive 
resistance to bacterial or protozoan intracellular pathogens.  
 
2.3.3 Strengths and weaknesses, and implications of findings 
Our results, presented here and in our previous work [275], indicate that the conditioned medium 
from PHT cells is broadly antiviral, inhibiting infection by viruses known to cause perinatal 
infection in humans. This inhibition was observed for RNA and DNA viruses. Previously we 
showed that viral inhibition was, in part, due to induction of autophagy, as recipient cells exposed 
to PHT medium demonstrated increased autophagy with internalizing virions localizing to 
autophagosomes. Further, the antiviral effect was mitigated when autophagy was blocked [275, 
317]. We previously showed that PHT conditioned medium contains high levels of miRNAs from 
the C19MC family that correspond to the expression level of these miRNAs in PHT cells [301]. 
Interestingly, our data show that the effect of C19MC miRNAs is markedly weaker than that of 
PHT conditioned medium [275], and not all viruses tested were sensitive to C19MC-associated 
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miRNAs previously shown to exert antiviral effects on VSV and HSV1. It is possible that 
expression of additional members of the C19MC miRNAs, or the entire miRNA cluster, might be 
needed for a more potent antiviral effect. In addition, a more effective miRNA delivery system 
(e.g., via exosomes) might potentiate the antiviral effect [275, 290]. This might be particularly 
relevant to VZV, in which infection might be enhanced by the initial stages of autophagy, but 
impaired by the complete, more effective autophagy process, which includes protein degradation 
[318].  
Our data do not rule out additional mechanisms for the antiviral effect of trophoblastic 
conditioned medium. We previously reported [275] that cells rendered incapable of responding to 
type I interferon retain their antiviral activity upon exposure to conditioned medium. Nonetheless, 
PHT conditioned medium may contain non-classical interferons or additional factors (see below) 
that contribute to the antiviral state and exhibit an additive or synergistic effect with the miRNAs. 
Importantly, the lack of effect on infection with either Listeria monocytogenes or Toxoplasma 
gondii suggests that the PHT conditioned medium and, to an extent, the C19MC miRNAs, 
stimulate a selective viral-specific response in non-trophoblast cells. Given the diversity of the 
viruses tested, it is possible that this response may inhibit viral infection at different points of the 
viral life cycle. Future studies have been designed to address the mechanisms underlying the 
antiviral effect, and elucidate the targets of the C19MC and other antiviral factors potentially 
present in PHT conditioned media.  
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2.4 MATERIALS AND METHODS 
2.4.1 Cells 
Human osteosarcoma U2OS, human foreskin fibroblast (HFF), melanoma-derived cells (MeWo), 
and TZM-bl cells [319] were cultured in DMEM (Corning, USA) supplemented with 10% FBS 
(Sigma, USA) and antibiotics. HFF cells were provided by Jon Boyle, Department of Biological 
Sciences, University of Pittsburgh. Human epithelial cells (Caco-2 cells, ATCC HTB-37) were 
cultured in Eagle’s MEM containing 20% heat-inactivated FBS and 10 U penicillin and 
streptomycin. Vero African green monkey kidney cells were maintained in DMEM supplemented 
with 5% FBS and antibiotics.  
PHT cells were acquired from healthy singleton term placentas, using the procedure 
previously described [47], with modifications [320, 321]. Cells were maintained in DMEM 
containing 10% bovine growth serum (HyClone, USA), 20 mM HEPES, and antibiotics at 37°C. 
Cells were maintained 72 h after plating, with cell quality monitored morphologically and by 
human chorionic gonadotropin (hCG) levels (ELISA, DRG International, USA) in the medium, 
which show a characteristic increase as cytotrophoblasts differentiate into syncytiotrophoblasts 
[322].  
2.4.2 Conditioned medium preparation 
Conditioned medium samples were collected from PHT cultures as previously described, and only 
medium that demonstrated at least 70% reduction in vesicular stomatitis virus (VSV) infection was 
used for subsequent infectivity assays [275]. Briefly, U2OS cells were exposed to conditioned or 
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non-conditioned PHT medium for 24 h, and infected with VSV at a multiplicity of infection (MOI) 
of 1 for 6 h or until cytopathic effect was evident. Cells were then lysed with 1mL Qiazol lysis 
reagent, and infection was quantified by RT-qPCR, as previously described [275]. 
2.4.3 Rubella plaque assays 
Vero cells were pre-exposed to either conditioned or non-conditioned medium and infected with 
rubella virus at an MOI of 10. Plaque assays were performed with serial dilution of the virus. One 
milliliter of each dilution and a control (PBS/1% FBS) were plated on 30 mm plates confluent with 
Vero cells, and the plates were incubated for 1 h at 37°C. Cells were overlaid with a liquid agar 
solution (60 mL 0.4% liquid agar, 34 mL 3X MEM, 1 mL FBS, 3 mL 5% NaHCO3, 0.1 mL 
penicillin/streptomycin and 0.1 mL diethylaminoethanol). The plates were incubated for 7 days at 
37°C. After incubation, the agar was removed, and the plates were stained with crystal violet 
solution to reveal plaques. Duplicate plaque assays were performed for each infection, and the 
final titer of each infection was the average of the two plaque assays. 
2.4.4 Alphavirus Luciferase assays 
Vero cells were pre-exposed to either conditioned or non-conditioned media for 24 h prior to 
infection. Reporter alphaviruses that expressed a cleavable firefly luciferase in between the capsid 
and PE2 proteins (as described in [306] were added to the cells at an MOI of 0.1 for 8 h and lysed 
with 1X Passive lysis buffer (Promega). Infection was quantified by measuring luciferase 
expression and normalized to protein level. Alphavirus constructs included eastern equine 
encephalitis virus (EEEV), Venezuelan equine encephalitis virus (VEEV), chikungunya virus 
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(CHIKV), and sindbis virus (SINV). These virus constructs were also used to infect U2OS cells 
transfected with miRNA mimics from the C19MC, as described below. These experiments were 
conducted with an MOI of 1 for EEEV, VEEV, and CHIKV while SINV was used at an MOI of 
0.1.  
2.4.5 HIV infectivity assay 
Utilizing the TZM-bl cell line, a HeLa cell derivative that are CD4+ and expresses CCR5 and 
CXCR4, as well as a Tat-inducible luciferase reporter, HIV-1 infectivity was quantified on the 
basis of relative luciferase expression [319, 323]. These cells, which are permissive to wild type 
HIV, were pre-exposed to PHT-conditioned media or non-conditioned media for 24 h prior to 
infection. HIV-1 NL4-3 was added at increasing concentrations, indicated in the figure legend. 
After 48 h, infected cells were washed with PBS and lysed in luciferase lysis buffer (Promega, 
USA) by rocking for 15 min. Lysates (40 μl) were transferred to white 96-well plates, and 50 μl 
luciferase reagent (Promega) was injected into each well. Luciferase activity was determined by 
detection of luminescence recorded by Synergy 2 SL luminescence microplate reader (BioTek, 
VT, USA). 
2.4.6 VZV Luciferase assays 
Varicella zoster virus (VZV) infectivity was measured using reporter viruses expressing firefly or 
renilla luciferase reporter enzymes respectively.  Recombinant viruses were developed from a 
VZV BAC using methods detailed previously [324]. The luciferase gene was placed directly 
downstream of either the immediate early gene encoding the latency associated regulatory protein 
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IE63 or the late VZV ORF9 gene encoding the abundant VZV tegument protein at the native locus, 
and was expressed as bi-cistronic  mRNAs with a T2A ribosome skipping motif  (MB Yee and PR 
Kinchington, manuscript in preparation. ).  VZV permissive HFF cells were pre-exposed to 
conditioned or non-conditioned media for 24 h. Cells were then infected with 1000 pfu/mL of 
either VZVORF9Luc or VZVORF63Luc vector for 48 h. Cells were lysed, and luciferase 
expression was quantified as described above.  
2.4.7 Fluorescence microscopy 
Toxoplasma gondii infection was quantified using a yellow fluorescent protein (YFP)-tagged RH 
strain provided by David Roos, University of Pennsylvania, as previously described [308]. HFF 
cell monolayers were cultured in eight-well chamber slides (Nunc Lab-Tek, Thermo-Fisher, USA) 
at 37°C, 5% CO2. Either conditioned or non-conditioned medium was added to the cells 24 h prior 
to infection. Toxoplasma gondii RH-YFP was added at an MOI of 0.5. Forty-eight h post-infection, 
cells were washed and fixed with 4% paraformaldehyde in PBS and permeabilized with 0.25% 
Triton X-100 in PBS. Fixed monolayers were then mounted with Vectashield (Vector 
Laboratories, USA) containing DAPI. Images were captured with an Olympus FluoView 1000 
laser scanning confocal microscope. Parasitophorous vacuole number and size, measured by 
region of interest length (uM), were quantified using Image J software (NIH, USA).  
2.4.8 Listeria infectivity assay  
Wild type Listeria monocytogenes (DP10403S) was cultured overnight at 37°C in brain and heart 
infusion (BHI). The following day, bacteria were diluted (1/20) in BHI and grown at 37°C until 
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OD 600 nm reached 0.7–0.8. Bacteria were washed three times with PBS and suspended in MEM 
at the indicated MOI. Caco-2 cells were plated in 24-well cell culture plates at a density of 40,000 
cells/well on glass coverslips coated with rat tail collagen. After 24 h, the cell culture medium was 
replaced with 500 µL conditioned or control medium, in triplicate, for 24 h. Caco-2 cells were 
washed with MEM and infected with L. monocytogenes at the indicated MOI. The bacterial 
suspension (500 µL MEM) was added to each well, and the cell culture plate was centrifuged at 
1,500 rpm for 2 min at room temperature. Caco-2 cells and bacteria were then co-incubated for 30 
min at 37°C, followed by two washes with warm MEM. Caco-2 cells were further incubated for 
the indicated times in the presence of conditioned or control medium supplemented with 15 µg/mL 
gentamicin [325, 326]. Cells were washed three times with warm PBS. A volume of 300 µL PBS 
containing 0.2% Triton X-100 was added to each well to lyse the Caco-2 cells. Cell lysates were 
diluted and plated on BHI agar plates to enumerate bacterial colony forming units. 
2.4.9 Mimic transfections 
Mimics for C19MC miRNAs (miRIDIAN) as well as a non-targeting control miRNA mimic were 
obtained from Thermo-Fisher USA as previously described [275]. U2OS cells were reverse 
transfected with miRNA mimics or miRNA mimic control (final concentration, 25 nM for each 
miRNA mimic), using DharmaFECT-1 transfection reagent (Thermo-Fisher) according to the 
manufacturers’ instructions. Cells were assayed 48 h post-transfection. 
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2.4.10 Statistics 
Experiments were performed at least three times as indicated in the legend of each figure. Data are 
presented as mean ± SD. Except where specified, Student’s t-test was used to determine statistical 
significance for virus infections when two sets were compared, and one-way analysis of variance 
(ANOVA), with Bonferroni’s correction for post hoc analysis of multiple comparisons, was used 
to determine statistical significance for reporter gene assays; p <0.05 was considered significant. 
2.4.11 Ethical approval 
PHT cells were cultured from term or near-term placentas collected by the Obstetrical Specimen 
Procurement Unit at Magee-Womens Hospital of the University of Pittsburgh Medical Center. 
Sample collection was conducted according to a protocol approved by the Institutional Review 
Board of the University of Pittsburgh. All specimens were de-identified.  
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3.0  TYPE III INTERFERONS PRODUCED BY HUMAN PLACENTAL 
TROPHOBLASTS CONFER PROTECTION AGAINST ZIKA VIRUS INFECTION5 
Avraham Bayer6, Nicholas J. Lennemann6, Yingshi Ouyang, John C Bramley, Stephanie Morosky, 
Ernesto Torres De Azeved Marques, Jr., Sarah Cherry, Yoel Sadovsky, and Carolyn B. Coyne.  
 
Data for figure 3-3D was provided by Stephanie Morosky. Data for figure 3-3E, F, G and figure 
3-6B was provided by Nicholas Lennemann. Data for figure 3-5A and C was provided by Carolyn 
Coyne. Data for figure 3-6C was provided by John Bramley.   
3.1 INTRODUCTION 
In eutherian organisms, the placenta acts as a physical and immunological barrier between the 
maternal and fetal compartments, and protects the developing fetus from the vertical transmission 
of viruses. In the human hemochorial placenta, the frontline of fetal protection are the 
syncytiotrophoblasts, which cover the surfaces of the human placental villous tree and are directly 
bathed in maternal blood following the establishment of the maternal circulatory system during 
the later stages of the first trimester.  
The mechanisms by which viruses can be transmitted vertically are multifaceted, and can 
involve entry into the gestational sac via direct hematogenous spread, trophoblastic transcellular 
                                                 
5 Reprinted with permission from Cell Press 
6 Co-first author 
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or paracellular pathways, transport within immune cells or infected sperm, pre-pregnancy uterine 
colonization, introduction during invasive procedures during pregnancy, and/or transvaginal 
ascending infection. The emerging ZIKV pandemic poses a new threat to the developing fetus. 
While usually causing relatively mild symptoms in non-pregnant individuals, ZIKV infection in 
Brazil has been associated with increased incidence of microcephaly [33, 327-329]. In addition, 
ZIKV infections have also been associated with other disorders such as placental insufficiency and 
fetal growth restriction, ocular disorders, other CNS anomalies, and even fetal death [32, 209].  
While direct evidence for a causal relationship between ZIKV infections and the 
development of abnormal pregnancy outcomes is still emerging, recent reports have directly 
identified the presence of viral RNA and infectious virus in the placentas, amniotic cavity and 
brains of fetuses that had developed fetal anomalies [208, 330, 331]. Interestingly, other 
flaviviruses, such as dengue virus (DENV), which is endemic in the regions of Brazil most 
impacted by the recent ZIKV outbreak, have not been associated with microcephaly or other 
congenital disorders, suggesting that ZIKV may exhibit unique mechanism(s) to directly infect 
and/or bypass the placental barrier, and access the fetal compartment and cause organ-specific 
damage.  
The innate immune system is a primary host defense strategy to suppress viral infections 
and converges on the induction of interferons (IFNs), which function in autocrine and paracrine 
manners to upregulate a cadre of other genes, known as interferon stimulated genes (ISGs). The 
effects of IFNs and ISGs are potent and wide-ranging; they are pro-inflammatory, enhance 
adaptive immunity, and are directly antiviral [332]. In most cell types, type I IFNs, which include 
IFNα and IFNβ, are the primary IFNs that are generated in response to viral infections. In contrast, 
cells of epithelial origin mount antiviral responses primarily mediated by type III IFNs, which 
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include IFNλ1-4 (also known as IL-29, IL-28A-C) [150]. The role of IFN signaling in the 
protection of placental trophoblasts from viral infections is unclear. Previous work has pointed to 
unidentified IFN(s) present in first trimester human placentas [333]. Ruminants express IFNτ at 
various stages of gestation [334], and the mouse placenta can produce IFNλs in response to Listeria 
monocytogenes infection [335].  
Here we show that primary human trophoblast (PHT) cells, isolated from full-term 
placentas, are refractory to infection by two strains of ZIKV, one derived from an African lineage, 
and one derived from an Asian lineage that exhibits >99% amino acid sequence similarity to strains 
currently circulating in Brazil [336]. We also found that conditioned medium isolated from PHT 
cells protected non-trophoblast cells from ZIKV infection through the constitutive release of the 
type III IFN IFNλ1. Our findings thus suggest that for ZIKV to infect syncytiotrophoblasts, it must 
overcome the restriction imparted by IFNλ1 and other syncytiotrophoblast-specific antiviral 
factors, and/or gain access to the fetal compartment by a mechanism that does not involve 
syncytiotrophoblast infection, at least in the later stages of pregnancy. 
3.2 RESULTS 
3.2.1 PHT cells produce an ISG inducing factor 
Using microarrays, we found that exposure of human fibrosarcoma HT1080 (2fTGH) cells to PHT 
CM induced a subset of previously characterized ISGs [87], which did not occur in HT1080 cells 
with defective signal transducer and activator of transcription 1 (STAT1; 2fTGH-U3A cells) 
signaling [337] (Figure 3-2A and Table 2-1). We obtained similar results when cells were treated 
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with IFN (Figure 3-2A), as previously described [338]. We confirmed these results by RT-qPCR 
in human osteosarcoma U2OS cells that were exposed to PHT CM, which led to the robust 
induction of two known ISGs, interferon induced protein 44 like (IFI44L) and interferon-induced 
protein with tetratricopeptide repeats 1 (IFIT1) (Figure 3-2B) and in human monocyte THP-1 cells 
as determined by an interferon regulatory factor (IRF)-inducible SEAP reporter assay (Figure 3-
5A)7.  In addition, using datasets from previously published RNASeq studies from our laboratory 
[46], we found that PHT cells express high levels of ISGs (Figure 3-2C). In contrast, the 
trophoblast cell line JEG-3 did not endogenously express ISGs (Figure 3-2C) and CM isolated 
from these cells did not induce ISGs in non-placental recipient cells (Figure 3-5B).  
In order to identify the ISG inducing factor present in our conditioned medium, we utilized 
an unbiased biochemical approach. Using gel filtration chromatography, we fractionated medium 
conditioned on PHT cells, which was confirmed to be potently antiviral, as well as robustly induce 
ISGs. We observed a single absorbance peak, which corresponded with elution fractions 
containing ISG inducing activity, measured by IFI44L induction using qPCR (Figures 3-1A and 
3-1C). These fractions were then further resolved using anionic exchange chromatography 
(MonoQ column), and we observed multiple peaks, with only one corresponding to ISG induction 
(Figure 3-1B and 3-1C). We next applied conditioned medium, pooled fractions from the gel 
filtration column, and two fractions from the anionic exchange column, corresponding to no ISG 
inducing activity and ISG inducing activity (MonoQ5 and MonoQ7, respectively) to an SDS-
PAGE gel, and silver-stained for proteins (Figure 3-1D). We observed a band unique to fractions 
that contained ISG inducing activity, which ran at 25 kd, consistent with the size of IFNλ.  
                                                 
7 Data provided by Dr. Carolyn Coyne (University of Pittsburgh, Pittsburgh PA) 
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Figure 3-1 – Biochemical isolation of ISG inducing ligand in conditioned medium. (A) PHT conditioned medium 
was loaded onto an HPLC S300 sepharose column equilibrated with PBS, and eluted into 5mL fractions. 
Protein absorbance was measured at 280nm. The peak at 0-10 mL corresponds with the void fraction (proteins 
too large to enter into the dextran beads. >300kd). (B) Pooled sepharose fractions were loaded onto a MonoQ 
anionic exchange column, and eluted into 2mL fractions, with increasing concentrations of NaCl (Up to 1M). 
Protein absorbance was measured at 280nm. Conductivity was measured in mS/cm. (C) IFI44L induction, 
normalized the amount of protein present in each fraction. Conditioned medium and pooled S300 fractions 
exhibited robust induction. Only fractions 7 and 8 from the MonoQ column demonstrated ISG induction. (D) 
Non-conditioned medium, conditioned medium, elutions from the S300 sepharose column, and two fractions 
from the MonoQ anionic column were run on an SDS-PAGE and then silver stained. MonoQ fractions were 
less complex in composition, with fraction 7 having a distinct band at approximately 25 kd.  
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During culturing in vitro, PHT cells undergo fusion to form syncytiotrophoblasts (Figure 
3-5C)6 similar to their natural differentiation process in vivo, which can be inhibited by exposing 
the cultures to DMSO [339]. We found that attenuation of PHT differentiation by DMSO reduced 
the ability of PHT CM to induce IFI44L in recipient cells (Figure 3-2D). Consistent with a role for 
syncytiotrophoblast fusion in the induction of ISGs, we found that exposure of PHT cells to 
epidermal growth factor (EGF), which promotes cell-cell fusion of trophoblasts [340], enhanced 
the ISG inducing properties of PHT CM (Figure 3-2E). Importantly, ISG induction in recipient 
cells was specific for PHT CM and did not occur when cells were exposed to CM from the 
trophoblast-derived cell lines BeWo, JEG-3, JAR, or HTR8 cells, suggesting that this induction is 
specific for CM derived from primary trophoblasts (Figure 3-2E and Figure 3-6B). Furthermore, 
although BeWo cell fusion can be stimulated by forskolin treatment [41], this treatment did not 
confer ISG-inducing properties to BeWo CM (Figure 3-2F), suggesting that cell-cell fusion alone 
is not sufficient to confer ISG inducing properties to trophoblasts. Lastly, we previously showed 
that PHT-derived exosomes released into PHT CM mediated some of the antiviral properties of 
PHT CM [275]. We found that CM depleted of vesicles was still capable of inducing ISGs in 
recipient cells (Figure 3-6D), indicating that an ISG-inducing pathway is present in PHT CM and 
bestows antiviral properties independently from PHT-derived exosomes.  
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Figure 3-2 - conditioned medium from PHT cells induces ISGs. (A), A heat map of interferon stimulated genes 
(ISGs) differentially expressed between control (TGH) or STAT1 signaling deficient (U3A) HT1080 cells 
exposed to purified IFNλ or PHT CM for 24hrs. (B), RT-qPCR analysis for IFI44L or IFIT1 in U2OS cells 
exposed to control PHT non-conditioned medium (NCM) or five independent preparations of PHT CM. Data 
are shown as a fold change from NCM. (C), Heat map of differentially expressed interferon stimulated genes 
(ISGs) between two cultures of JEG-3 cells and a single preparation of PHT cells as assessed by RNASeq 
(p<0.05). Data related to 3-2C was provided by Dr. Carolyn Coyne (University of Pittsburgh, Pittsburgh PA) 
(D), Two preparations of PHT cells were exposed to DMSO to inhibit cell fusion, CM collected, and then IFI44L 
induction assessed by RT-qPCR (left y axis). In parallel, the levels of human chorionic gonadotropin (hCG) 
were determined by ELISA (right y axis). (E), BeWo cells were exposed to forskolin to induce fusion, CM 
collected, and ISG induction in CM-exposed cells assessed by RT-qPCR (for IFI44L, left y axis). In parallel, 
the levels of hCG were assessed by ELISA (right y axis). (F), In (B), (D-F), data are shown as mean ± standard 
deviation (*p<0.05, **p<0.01, ***p<0.001, ns not significant). The color intensity in (A) and (C) indicates the 
level of gene expression (yellow for up-regulation and blue for down-regulation), and grey indicates that no 
transcripts were detected in that sample. 
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3.2.2  PHT cells release the type III IFN IFN1  
We found by ELISAs that PHT CM contained negligible levels of IFNβ that were comparable to 
those in control non-CM, but contained IFNλ1, and to a lesser extent, IFNλ2, which was detected 
in one PHT preparation (Figure 3-3A). In addition, PHT cells expressed high levels of IFNλ1 
mRNA (Figure 3-3B)8, which were consistent with the levels induced in non-PHT cells (HBMEC) 
transfected with the synthetic ligand polyinosinic-polycytidylic acid (poly I:C) to induce IFN 
production (Figure 3-3B)9. In addition, we found that anti-IFNλ1/2 neutralizing antibodies 
partially inhibited the induction of the ISG IFI44L by PHT CM (Figure 3C). Furthermore, although 
CM isolated from uninfected trophoblast-derived cell lines did not contain detectable levels of 
IFNλ1 (Figure 3-6A), we found that these cells potently induced type III IFNs, primarily IFNλ1, 
in response to infection by Sendai Virus (SeV, Figure 3-3D)8 and by both DENV and ZIKV (Figure 
3E)10. In contrast, PHT cells did not induce IFNλ1 or the ISG 2'-5'-Oligoadenylate Synthetase 1 
(OAS1) in response to ZIKV, or DENV, infection, yet were highly resistant to infection when 
compared to JEG-3 cells (Figure 3-3F and Figure 3-6B)9. However, PHT cells do induce both 
IFNλ1 and ISGs in response to toll like receptor 3 (TLR3) stimulation by poly I:C (Figure 3-7C). 
Finally, we found that RNAi-mediated silencing of a subunit of the type III IFN receptor (IL28RA) 
partially restored ZIKV infection in recipient cells exposed to PHT CM depleted of vesicles 
(Figure 3-3G)9. Collectively, these data point to a direct role for type III IFNs, particularly IFNλ1, 
in the antiviral signaling of placental syncytiotrophoblasts to viral infections, including ZIKV.   
                                                 
8 Data provided by John C Bramley (University of Pittsburgh, Pittsburgh PA) 
9 Data provided by Stephanie Morosky (University of Pittsburgh, Pittsburgh PA) 
10 Data provided by Dr. Nicholas Lennemann (University of Pittsburgh, Pittsburgh PA) 
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Figure 3-3 - Conditioned medium from PHT cells contains IFNλ1, which is required for ISG induction. (A), 
ELISA for IFNβ, IFNλ1, and IFNλ2 in four independent PHT CM preparations (left y axis). In parallel, the 
extent of ISG induction in each sample was determined by RT-qPCR for the levels of IFI44L induced in U2OS 
cells exposed to the sample (right y axis). (B), The levels of IFNβ and IFNλ1 mRNA in three preparations of 
PHT cells was assessed by RT-qPCR. In parallel, IFNβ and IFNλ1 mRNA levels were determined in mock-
treated HBMEC, or in HBMEC exposed to 10μg poly I:C (‘floated’ in the medium) for ~24hrs. Data are shown 
as a fold change from mock-treated HBMEC cells. Data related to 3-3B was provided by Stephanie Morosky 
(University of Pittsburgh, Pittsburgh PA) (C), Level of ISG induction (as assessed by IFI44L RT-qPCR) in 
U2OS cells exposed to purified IFNλ1, or to three preparations of PHT CM incubated with a non-neutralizing 
monoclonal antibody (MOPC21) or anti-IFNλ-1-3 neutralizing antibodies. (D), RT-qPCR for IFNβ, IFNλ1, or 
IFNλ2 in indicated trophoblast cell lines infected with Sendai virus (SeV) for ~24hrs. Data related to figure 3-
3D provided by Stephanie Morosky (University of Pittsburgh, Pittsburgh PA) (E), RT-qPCR for IFNλ1 or 
IFNλ2 in the indicated trophoblast cell lines infected with DENV or ZIKVM for ~24hrs. (F), RT-qPCR for 
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IFN1 or OAS1 in JEG-3 or PHT cells infected with DENV, ZIKVM, or  ZIKVC for ~24hrs. (G), ZIKVC 
infection in HBMEC transfected with control siRNA (CONsi) or IL28RA siRNAs and exposed to PHT 
conditioned medium depleted of vesicles for ~24hrs prior to infection. In all panels, data are shown as mean  ± 
standard deviation (*p<0.05, **p<0.01, ***p<0.001, ns not significant). Data related to figure 3-3(E-G) 
provided by Dr. Nicholas Lennemann (University of Pittsburgh, Pittsburgh PA) 
 
3.3 DISCUSSION 
The strong association between ZIKV infection in pregnant women and the development of fetal 
growth restriction and/or CNS and other fetal congenital abnormalities, in addition to the positive 
culture of ZIKV from feto-placental tissues of affected pregnancies, suggest that ZIKV is capable 
of gaining access into the intrauterine cavity to directly affect fetal development. Our work 
presented here suggests that ZIKV is unlikely to access the fetal compartment by direct replication 
in placental syncytiotrophoblasts, as least in the later stages of pregnancy, unless ZIKV can bypass 
the antiviral properties of type III IFNs and other syncytiotrophoblast-derived antiviral pathways. 
Because we observed potent protection from ZIKV infection by type III IFNs, specifically IFNλ1, 
which is constitutively produced by syncytiotrophoblasts, it likely functions in an autocrine 
manner to protect these cells from viral infections. In addition, we show that trophoblast-derived 
IFNλ1 protects non-placental cells from ZIKV infection in a paracrine manner. A schematic of the 
human placenta and the mechanisms by which IFNλ1 protects syncytiotrophoblasts from ZIKV 
infection is shown in Figure 3-4. Our work thus provides evidence that ZIKV may not directly 
infect placental villous syncytiotrophoblasts during the later stages of pregnancy, suggesting 
instead that the virus must either evade the potent type III IFN antiviral signaling pathways 
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generated by these cells and/or bypass these cells through an as-yet-unknown pathway to gain 
access to the fetal compartment.   
Our previous studies implicated a role for trophoblast-specific miRNAs associated with the 
placental-specific chromosome 19 miRNA cluster (C19MC), contained within PHT-derived 
exosomes, as part of the antiviral arsenal secreted by PHT cells [275, 341]. Indeed, our work 
presented here demonstrates another facet of the antiviral mechanisms utilized by PHTs to protect 
the developing fetus.  These potent antiviral pathways likely function in parallel to provide 
multiple mechanisms to protect syncytiotrophoblasts, and other cell types at the maternal-fetal 
interface, from ZIKV, and other viral infections. It is also possible that other as-yet-undiscovered 
pathways intrinsic to placental trophoblasts provide additional pathways to protect these cells from 
viral infections. While we have not been able to reliably measure IFNλ in the plasma of pregnant 
women, this may be because IFNλ is below the limits of detection in the expanded plasma volume 
of pregnant women and/or that the effects of IFNλ are local, affecting trophoblastic and non-
trophoblastic placental cells (such as villous fibroblasts) in the immediate vicinity of the feto-
placental unit.  
Type III IFNs share significant structural homology with members of the IL-10 cytokine 
family [135], but induce ISGs similar to type I IFNs [125] through a distinct receptor [126]. We 
found that PHT cells expressed high levels of IFNλ1. Remarkably, IFNλ1 was constitutively 
released from PHT cells and did not require the activation of antiviral innate immune signaling 
pathways to become induced. Thus, in addition to studies that implicate an important role for type 
III IFNs in antiviral signaling in the respiratory and gastrointestinal tracts and the blood-brain 
barrier [150], our work directly points to a role for type III IFNs, specifically IFNλ1, in antiviral 
signaling at the maternal-fetal interface. Although type I IFNs are conserved between mice and 
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humans, there is significant divergence in the type III IFN pathway, where humans express IFNλ1-
4 and mice express only IFNλ2 and IFNλ3. PHT cells expressed IFNλ2 at significantly lower levels 
than IFNλ1 and did not express mRNA for either IFNλ3 or IFNλ4. Thus, in addition to the 
morphological differences between the human and mouse placentas [342], these data suggest that 
the IFNλ1-mediated antiviral properties of placental syncytiotrophoblasts may be distinct between 
humans and mice, which may complicate the use of the mouse placenta as a model for viral 
infections of the placenta during human pregnancy.  
Another important implication of our work is that cells that do not express the type IIII IFN 
receptor, or do not respond robustly to type III IFNs, may be more susceptible to ZIKV infection, 
particularly at the maternal-fetal interface. In mice, the expression of the alpha subunit of the IFN-
lambda receptor (IL-28RA) is restricted to epithelial-derived cells, which respond most robustly 
to type III IFNs [343]. Recent evidence also supports a role for type III IFNs in the microvascular 
endothelium comprising the blood brain barrier [148]. Because syncytiotrophoblasts and other 
trophoblasts are epithelial cells, and are likely protected by the potent stimulation of ISGs in 
response to their constitutive production of IFNλ1, our data suggest that ZIKV may invade the 
intrauterine cavity by mechanisms that are distinct from direct infection of villous trophoblast. In 
addition to the trophoblast cell layers, the human placenta is also composed of mesenchymal cells, 
placental-specific macrophages (termed Hofbauer cells), and fibroblasts, located within the villous 
core between trophoblasts and fetal vessels. These cell types may exhibit differences in their 
responsiveness to IFNλs.  It addition, it is also possible that the less differentiated, first trimester 
trophoblasts as well as extravillous trophoblasts are more permissive than late pregnancy villous 
trophoblasts to ZIKV infection and/or the antiviral effects of IFNλs. Finally, it is possible that the 
levels of IFNλ1 vary throughout pregnancy, or between individuals, which could markedly impact 
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the ability of the virus to infect the syncytiotrophoblast cell layer at specific times during 
pregnancy, or in specific individuals 
The rapidly emerging human health crisis associated with the ZIKV epidemic highlights 
the growing need to identify mechanisms by which ZIKV accesses the fetal compartment. These 
data will be instrumental in order to design therapeutic measures to limit ZIKV replication and/or 
spread. Our experimental cell system is directly relevant to the study of congenital ZIKV 
infections, defining unique antiviral mechanisms at play in this specialized environment. We 
provide evidence that ZIKV is unlikely to access the fetal compartment by its direction infection 
of late pregnancy villous syncytiotrophoblasts, and potentially neighboring cells that express 
INFLR, due to the role of type III IFNs in the antiviral defense produced by villous trophoblasts, 
and suggests that the virus may circumnavigate these cells or overcome this restriction in vivo in 
order to bypass the placental barrier.  
 
Figure 3-4 - Schematic depicting the structure of the human placenta and the role of IFNλ1 in protecting against 
ZIKV infection. (A), The intrauterine environment during human pregnancy. Embryonic structures include 
the villous tree of the human hemochorial placenta and the umbilical cord, which transfers blood between the 
placenta and the fetus. (B), An overview of a single placental villus. Extravillous trophoblasts invade and anchor 
the placenta to the maternal decidua and to the inner third of the myometrium. The villous tree consists of both 
floating and anchoring villi. Multinucleated syncytiotrophoblasts overlie the surfaces of the villous tree and are 
in direct contact with maternal blood (which fills the intervillous space (IVS) once the placenta is fully formed. 
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Mononuclear cytotrophoblasts are subjacent to the syncytiotrophoblasts and the basement membrane of the 
villous tree, and serve to replenish the syncytiotrophoblast layer throughout pregnancy. (C), In the work 
presented here, we show that syncytiotrophoblasts release IFN1 that can act in both autocrine and paracrine 
manners to induce ISGs, which protect against ZIKV, and other virus, infections. The paracrine function of 
IFN could work locally within the direct maternal-fetal compartment, or might circulate more systemically 
to act on other maternal target cells. Schematic created by Dr. Carolyn Coyne (University of Pittsburgh, 
Pittsburgh PA) 
 
3.4 MATERIALS AND METHODS 
3.4.1 Culture of primary human trophoblasts 
PHT cells were isolated from healthy singleton term placentas using the trypsin-DNAse-
dispase/Percoll method as described [47], with previously published modifications under an 
exempt protocol approved by the institutional review board at the University of Pittsburgh. Patients 
provided written consent for the use of de-identified and discarded tissues for research purposes 
upon admission to the hospital. Cells were maintained in DMEM (Sigma) containing 10% FBS 
(HyClone) and antibiotics at 37°C in a 5% CO2 air atmosphere. Cells were then maintained for 72 
h after plating, with cell quality ensured by microscopy and production of human chorionic 
gonadotropin (hCG), determined by ELISA (DRG international). The cells exhibited a 
characteristic increase in medium hCG levels as the cytotrophoblasts differentiated into 
syncytiotrophoblasts.  
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3.4.2 Cells and viruses 
Human osteosarcoma U2OS cells, Vero cells, 2fTGH (STAT1 wild-type) and U3A (STAT1 
mutant) fibrosarcoma cells (previously described [337]) were cultured in DMEM supplemented 
with 10% FBS and antibiotics. BeWo cells were maintained in F12K Kaighn’s modified medium 
supplemented with 10% FBS and antibiotics. JAR cells and immortalized, human, first-trimester, 
extravillous trophoblast cells (HTR8/SVneo) were maintained in RPMI 1640 medium 
supplemented with 10% FBS with antibiotics. Human choriocarcinoma JEG-3 cells were 
maintained in EMEM medium, supplemented with 10% FBS with antibiotics. Human brain 
microvascular endothelial cells (HBMECs) were maintained in RPMI 1640 medium supplemented 
with 10% FBS, 10% NuSerum, MEM vitamins, non-essential amino acids, sodium pyruvate, and 
antibiotics. THP-1 cells stably expressing an interferon regulatory factor (IRF)-inducible SEAP 
reporter construct were obtained from Invivogen and were cultured in RPMI medium, 2mM L-
glutamine, 10% FBS supplemented with 100 µg/ml Zeocin. SEAP levels in tissue culture medium 
were assessed according by QUANTI-Blue to the manufacturer’s instructions. HeLa CCL-2 cells 
were maintained in MEM supplemented with 10% FBS, non-essential amino acids, sodium 
pyruvate, and antibiotics. Development of HeLa cells stably propagating a DENV subgenomic 
replicon has been previously described [344]. Plasmids used to generate stable replicon cells were 
provided by Theodore Pierson (NIAID). Aedes albopictus midgut C6/36 cells were maintained in 
DMEM supplemented with 10% FBS and antibiotics at 28°C in a 5% CO2 air atmosphere. 
 
DENV2 16681 and ZIKV FSS13025 (Cambodian origin) were propagated in C6/36 cells, 
as previously described [345]. ZIKV MR766 (Ugandan origin) was propagated in Vero cells. Viral 
titers were determined by fluorescent focus assay, as previously described [346], using anti-DENV 
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envelope protein monoclonal antibody 4G2 (provided by Margaret Kielian, Albert Einstein 
College of Medicine) for DENV and anti-double stranded RNA monoclonal antibody J2 (provided 
by Saumendra Sarkar, University of Pittsburgh) for ZIKV. SeV was purchased from Charles River 
Laboratories. Experiments measuring productive DENV and ZIKV infection were performed with 
1 to 3 focus forming units/cell for 24 h, unless otherwise stated, and SeV was used at 100 
hemagglutination units/cell for 24 h. Infection was determined by either RT-qPCR or 
immunofluorescence microscopy, as stated in the figure legends. 
 
3.4.3 Preparation and characterization of conditioned medium 
CM samples from PHT cells or other cells were harvested at 72h after plating followed by 
centrifugation at 800 xg for 5 min. Non-conditioned medium (NCM) was complete PHT medium 
(described above) that had not been exposed to PHT cells. Recipient cells were exposed to 
conditioned medium for ~24 h before assays. Vesicle depleted conditioned medium was generated 
by three centrifugation steps: 2,500 xg for 5 min at room temperature, followed by 12,000 xg for 
20 min at room temperature, and 100,000 xg for 2 h at 4°C. 
 
Levels of IFNλ1, IFNλ2 (R&D Systems), and IFNβ (PBL Source) present in CM produced 
from individual PHT cell preparations were analyzed by ELISA, according to manufacturer 
protocol. Antiviral activity of CM preparations was determined in HBMEC exposed to CM for 24 
h prior to infection with DENV, ZIKVM, or ZIKVC. 
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3.4.4 Neutralization assay 
Conditioned medium diluted 4-fold, recombinant IFNβ (100 U/mL; PBL Source), or recombinant 
IFNλ1 and IFNλ2 (5ng/mL each; R&D Systems) was incubated with neutralizing antibodies 
against IFNβ (200ng/mL; R&D Systems), IFNλ1 and IFNλ2 (1µg/mL each; R&D Systems), or 
mouse IgG1 (1µg/mL; Sigma) for 1 h at room temperature then added to cells. After 24 h of 
exposure, the RNA was harvested and analyzed for induction of ISGs. 
 
3.4.5 Differentiation assay 
PHT differentiation was blocked by growing the cells in the presence of 1.5% dimethyl sulfoxide 
(DMSO) [339]. The levels of hCG in DMSO-exposed cells confirmed the attenuation of 
differentiation by DMSO. For BeWo cell differentiation, BeWo cells were exposed to 25 nM of 
Forskolin for 24 h, and differentiation was confirmed by increased medium level of hCG. For EGF 
exposure, PHT medium was replaced 4 h post-plating and with medium containing 10g/mL EGF 
(BD Biosciences), which was replenished with fresh medium containing EGF before medium was 
harvested at 48 h. 
 
3.4.6 RNA extraction, cDNA synthesis, and Real-Time quantitative PCR 
For cellular mRNA analysis, total RNA was extracted using TRI reagent (MRC) or GenElute total 
RNA miniprep kit (Sigma) according to the manufacturer protocol. RNA samples were treated 
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with RNase-free DNAse (Qiagen or Sigma). Total RNA was reverse transcribed using HiCapacity 
cDNA synthesis kit (Applied Biosystems) or iScript cDNA synthesis kit (Bio-Rad) according to 
the manufacturer protocol. Strand specific cDNA was produced with primers targeting the negative 
RNA strand DENV or ZIKV using iScript Select cDNA Synthesis kit (Bio-Rad). RT-qPCR was 
performed using SYBR select or iQ SYBR green supermix (BioRad) in a StepOnePlus real-time 
PCR system (Applied Biosystems), ViiA 7 systems (Applied Biosystems), or CFX96 Real-Time 
system (Bio-Rad). Gene expression was calculated using the 2-delta delta CT method normalized 
to GAPDH or actin. Primer sequences were as follows: GAPDH (5’- 
GAAGGTCGGAGTCAACGGATTT -3' and 5’- GAATTTGCCATGGGTGGAAT -3'); Actin 
(5’-ACTGGGACGACATGGAGAAAA-3' and 5’-GCCACACGCAGCTC-3'); IFI44L (5’-
TGCAGAGAGGATGAGAATATC-3' and 5’-ACTAAAGTGGATGATTGCAG-3'); IFIT1 (5’-
CAACCAAGCAAATGTGAGGA-3' and 5’-GGAGACTTGCCTGGTGAAAA-3'); IFNβ (5’-
GAGCTACAACTTGCTTGGATTC-3' and 5’-CAAGCCTCCCATTCAATTGC-3'); IFNλ1 (5’-
CGCCTTGGAAGAGTCACTCA-3' and 5’-GAAGCCTCAGGTCCCAATTC-3'); IFNλ2 (5’-
ACATAGCCCAGTTCAAGTC-3' and 5’-GACTCTTCTAAGGCATCTTTG-3'); IFNAR1 (5’-
CAGTTGAAAATGAACTACCTCC-3' and 5’-ACTTGAAAGGTCATGTTTGC-3'); IL28RA 
(5’-ATCCTCAGTTAACCTACACC-3' and 5’-CAGATACTCCACCACAAAAC-3'); OAS1 5’-
ATAAAAGCAAACAGGTCTGG-3’ and 5’- TCTGGCAAGAGATAGTCTTC-3’); ZIKV (5’-
AGATGACTGCGTTGTGAAGC-3' and 5’-GAGCAGAACGGGACTTCTTC-3'); and DENV 
(5’-AGTTGTTAGTCTACGTGGACCGA-3' and 5’-CGCGTTTCAGCATATTGAAAG-3'). The 
specificity of ZIKV and DENV primers were confirmed by RT-qPCR analysis (Figure 3-5F).   
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3.4.7 RNASeq and microarray analyses 
RNASeq from JEG3 and PHT cells was performed as previously described [46]. Briefly, libraries 
were prepared with the NEB Ultra Library Preparation kit and library quality was determined using 
the Qubit assay and the Agilent 2100 Bioanalyzer. Sequencing was performed with the Illumina 
HiSeq2500 rapid-run mode on one flow cell (two lanes). CLC Genomics Workbench 8 (Qiagen) 
was used to process, normalize, and map sequence data to the human reference genome (hg19). 
Differentially expressed genes were identified using DESeq2 [347] with a significance cut-off of 
0.05, and heat maps were generated using MeViewer software. 
We used high-throughput microarray analysis as previously described [338], to screen for 
transcriptional changes in control (2fTGH) vs. STAT1 signaling deficient (U3A) HT1080 cells, 
both exposed to 100U of purified IFNβ (PBL) or PHT CM for 24 h. In parallel, mock-treated 
2fTGH and U3A were also included and were used to identify differentially expressed genes in 
IFNβ- and CM-treated cells.   
 
3.4.8 Immunofluorescence and transmission electron microscopy 
Cells cultured in chamber slides (LabTek, Nunc) were fixed in ice cold methanol, washed, 
incubated with primary antibody for 1 h, followed by Alexa Fluor conjugated secondary antibody 
for 30 min (Figure S1G). Slides were mounted with VectaShield (Vector Laboratories) containing 
4′,6-diamidino-2-phenylindole (DAPI). Images were captured on an Olympus IX83 inverted 
fluorescent microscope and analyzed using ImageJ. 
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For transmission electron microscopy, cells were fixed in 2.5% glutaraldehyde as 
previously described [275]. Micrographs were captured using a JEOL 1011 transmission electron 
microscope. 
 
3.4.9 RNAi mediated silencing  
HBMECs were reverse transfected with 25nM Mission siRNA Universal Negative Control 
(Sigma) or two pooled Silencer Select siRNAs targeting IL28RA (Ambion). At ~48 h post 
transfection, cells were exposed to PHT CM depleted of vesicles for 24 h followed by infection 
with ZIKVC. At 24 h post-infection, RNA was isolated and infection analyzed by RT-qPCR. 
3.4.10 Protein fractionation 
Gel filtration chromatography was accomplished using an AKTA FPLC and Superdex S75 300GL 
size exclusion column (GE Healthcare) equilibrated in PBS at 4° C. Protein elution was measured 
at 280 nm. Elutions from the S75 300GL SEC were pooled, and filter sterilized using 0.20 μm 
sterile syringe filters (Corning). These samples were loaded onto an anion exchange column 
(MonoQ, GE Healthcare) and eluted with a salt gradient (NaCl up to 1M). Salt concentration was 
measured by conductivity.  
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3.4.11 Micro BCA protein assay 
Protein concentration from the non-conditioned medium, conditioned medium, and fractions was 
measured using a Micro BCA kit (Thermo Scientific) according to the manufacturers protocol.  
3.4.12 Statistics 
Experiments were performed at least three times as indicated in the figure legends or as detailed. 
Data are presented as mean ± standard deviation. Except were specified, a Student’s t- test was 
used to determine statistical significance for virus infection assays when two sets were compared, 
and one-way ANOVA with Bonferroni’s correction used for post hoc multiple comparisons was 
used to determine statistical significance. Specific p-values are detailed in the figure legends.   
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3.5 SUPPLEMENTAL INFORMATION 
 
Figure 3-5 Supplemental figure related to figure 3.2. (A), SEAP levels in the cell culture medium of THP-1 ISG-
Blue cells treated with NCM or four preparations of PHT CM using the QUANTI-Blue assay. Data are shown 
as OD655. (B), RT-qPCR for IFI44L in U2OS cells exposed to non-conditioned medium (NCM) or the CM 
from the indicated trophoblast cell lines, or from PHT cells. Data are shown as a fold change from NCM 
matched control. Data are shown as mean ± standard deviation,*** p<0.001. (C), Confocal micrograph of PHT 
cells. DAPI-stained nuclei are shown in blue, actin is shown in green, and cytokeratin-19 is shown in red. White 
arrows denote multinucleated syncytiotrophoblasts. (D), The level of IFI44L induction from PHT CM depleted 
of exosomes as determined by RT-qPCR. Data related to figure 3-6A and 3-6C provided by Dr. Carolyn Coyne 
(University of Pittsburgh, Pittsburgh PA) 
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Supplemental Figure 3-6 (A), ELISA for IFNλ1 in the medium from the indicated trophoblast-derived cell lines 
and from two independent preparations of PHT cells. (B), RT-qPCR for total vRNA in DENV, ZIKVM, or 
ZIKVC infected PHT cells, or in JEG-3 cells, which are matched to the data shown in Figure 3F. (C), RT-qPCR 
for IFNλ1, IFNλ2, and IFIT3 in mock-treated PHT cells or in cells incubated with 10μM pI:C (‘floating’). Data 
are shown as mean ± standard deviation. Data related to figure 3-7B provided by Dr. Nicholas Lennemann 
(University of Pittsburgh, Pittsburgh PA) 
 
Table 3-1 - Related to Figure 2 
Gene TGH.(IFNvCON) U3A.(IFNvCON) TGH.(CMvCON) U3A.(CMvCON) 
MX1 4.896358663 0.388294157 3.263410147 -0.271622325 
GCA 4.517715329 -0.395744301 3.044818852 -0.833194482 
PHF11 4.485801453 0.10987201 2.825646995 0.383666568 
RSAD2 4.804955007 0.615113013 2.730072248 -1.189510583 
MX2 4.77559591 0.782529649 2.640376575 0.124378476 
HESX1 2.395931562 -0.047611623 2.490728829 0.279331787 
TDRD7 2.586238529 0.321782908 2.310714294 0.921060686 
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USP18 5.730437534 0.115370405 2.284359399 0.329455223 
IFI44L 8.913031589 0.924534909 2.164678967 0.063553645 
IFIH1 5.001070005 0.395044768 2.112201 -0.911184453 
IFI27 5.745581718 2.492179908 1.95267877 -0.240694057 
DTX3L 2.689138978 0.689019188 1.796073483 0.290002187 
OAS2 5.145123424 0.88088955 1.745493029 0.018104964 
PNPT1 2.829664487 0.172126122 1.668212042 0.890894168 
DDX58 4.206286299 0.741261345 1.615580997 1.099575989 
TLR3 2.45286905 2.253218622 1.519366804 -0.403987308 
PLSCR1 2.883172842 0.150574065 1.503924418 0.004749209 
PPM1K 2.277909683 0.564597375 1.379270543 1.575616035 
GBP1 4.91359994 0.298253437 1.365440211 0.381459194 
PLEKHA4 2.912923786 0.159430372 1.326477622 -0.034119997 
ANKRD22 6.079696462 1.555961834 1.27404633 0.29687178 
DHX58 5.511157214 0.283502849 1.223487303 -0.358185471 
OAS3 3.402291872 0.556019625 1.204068818 0.223923078 
CXCL11 3.472110173 1.051661136 1.055936092 -0.94359852 
DDX60 5.043230844 0.95734797 0.959847314 -1.017719499 
NMI 3.188299747 0.487135496 0.802370817 -0.45530595 
IFI44 4.73855272 1.023600087 0.782485247 -0.872754664 
RTP4 5.280825809 1.38514923 0.723133744 -0.525119712 
IRF9 3.433175564 0.712113478 0.722101364 -0.301602672 
BATF2 3.02129754 0.339364537 0.710870521 0.022435634 
IFI6 4.645271804 1.862423076 0.692992535 -0.276437265 
IFIT5 2.934888011 0.518821813 0.688222994 0.572404181 
SLC15A3 5.760020987 -0.502168785 0.521449159 -0.009730073 
IFIT2 4.608131777 0.227396865 0.487998324 -0.656114793 
EIF2AK2 2.904046139 0.411798817 0.445902929 -0.295878668 
TRIM5 2.049548111 -0.276493838 0.416625857 0.691593987 
TRIM21 2.244186934 0.219315257 0.378410223 -0.230646938 
GBP5 3.930868705 -0.03250477 0.28785213 -0.547688963 
STAT2 2.093108083 0.169721686 0.261996504 0.050812407 
 
Table 3.1 - Expression of ISGs as determined by microarray analyses in 2fTGH (TGH) or U3A HT1080 
cells treated with 100U of purified IFNβ (in grey) or PHT CM (in purple). Values shown are log2 fold 
changes from untreated control cells. 
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4.0  CONCLUSIONS AND FUTURE CHALLENGES 
During pregnancy, microbial infections can compromise the health of the mother, as well as the 
health of her developing fetus. There are many pathogens that have been linked to severe 
congenital complications, infecting the fetus and resulting in miscarriages, fetal death, and 
developmental abnormalities such as growth restriction, microcephaly, and cardiac abnormalities. 
Even if an infection does not directly cross the placenta, severe maternal infection may 
compromise maternal homeostatic adaptation to pregnancy, with a secondary, adverse effect on 
pregnancy outcome. Understanding the mechanism deployed by the placenta to prevent fetal 
infections, and the mechanism pathogens use to subvert the placental barrier, will help establish 
strategies to prevent adverse pregnancy outcomes.  
The work presented in this thesis identifies potent and broadly acting pathways by which 
the human placenta defends against viral infections. Our cultures of PHT cells, which model the 
trophoblasts during the third trimester (including the differentiation of cytotrophoblasts to 
syncytiotrophoblasts), are resistant to a diverse panel of viruses, including ZIKV. We find that this 
viral resistance can be conferred to non-placental cells through exposure to conditioned medium. 
Furthermore, individual miRNA mimics, representative of some of the C19MC miRNAs, are able 
to confer resistance to pathogens associated with perinatal infections. We demonstrate that PHT 
cells constitutively produce the type III IFN, IFNλ1, which elicits a robust induction of interferon-
stimulated genes. Taken together, our results suggest that the term placenta, through at least two 
separate pathways, is able to confer resistance to non-placental cells. Considering that the miRNAs 
packaged in exosomes, as well as high levels of IFNλ1, are released by the syncytiotrophoblasts 
into maternal circulation, it is possible that the placenta can confer resistance to viral infection 
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broadly to the mother, and potentially also to the fetus. While we were unable to detect IFNλ in 
plasma samples from pregnant women, detection could be made more difficult as a result of 
dilution in the expanded maternal blood volume during pregnancy. This may suggest that IFNλ is 
acting locally, effecting tissues in the uterine environment that express the IFNLR. Future 
experiments testing cord blood may provide evidence for transport of IFNλ to fetal tissue.  
In the concluding sections, we address areas of continuing research in the lab, focusing on 
understanding the regulation and function of the chromosome 19 microRNA cluster (including the 
induction of autophagy), regulation of IFNλ, and characterization of the trophoblast derived 
extracellular vesicles. Lastly, we discuss remaining questions in the field, regarding how viruses 
and other pathogens circumvent the placental barrier, and what mechanisms of entry are being 
employed, leading to congenital disease. 
4.1 CONDITIONED MEDIUM AND C19MCS 
In chapter 2, we presented data demonstrating that conditioned medium from PHT cells and the 
individual miRNA mimic miR-517-3p from the chromosome 19 miRNA cluster were able to 
confer resistance to non-placental cells infected with viruses associated with perinatal infections. 
Building on our previous studies, in which we demonstrated that PHT cells were resistant to a 
diverse panel of RNA and DNA viruses [275], we have broadened our studies to include rubella 
virus and other members of the togaviridae, varicella zoster virus, HIV, as well as the protozoan 
parasite Toxoplasma gondii, and the bacterium Listeria monocytogenes. We demonstrate that PHT 
conditioned medium has broad antiviral capacity, significantly reducing infection in all the viruses 
we had tested. This breadth of antiviral activity, capable of inhibiting viruses with distinct viral 
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lifecycles, reflects the multifaceted functions of the different ISGs that are induced upon IFN 
stimulation. Furthermore, we note that conditioned medium exposed to cells prior to the 
establishment of infection was able to confer resistance, however we observe no reduction in 
infection in cells that are exposed to conditioned medium from an already established infection 
(Appendix Figure 4-2D).  
4.1.1 The differences between PHT CM and C19MC miRNA mimics 
We observed disparate results when comparing the antiviral effects of PHT conditioned medium 
to the introduction of individual miRNA mimics from the C19MC family. While the conditioned 
medium consistently conferred significant protection to non-placental recipient cells (HeLa, 
U2OS, HBMEC, HUVEC, HFF, Vero, HT1080) from viral infection, the miRNA mimic miR-
517-3p only limited the replication of select viruses tested (Figure 2-1C and Figure 2-3B), 
indicating that the conditioned medium contained additional factors contributing to the antiviral 
effects. As we demonstrated in chapter 3, the conditioned medium, in addition to the exosome 
packaged miRNAs, contains significant levels of IFNλ1, a potent inhibitor of viral infection. This 
partially explains differences observed between the CM and miRNA mimic experiments presented 
in chapter 2. However, it does not address why individual miRNAs, which were previously 
demonstrated to be antiviral against VSV infection, demonstrated no significant effect on HIV, 
EEEV, or VEEV (Figure 2-1C). These pathogens may have mechanisms to subvert miRNA 
mediated antiviral activity, likely downstream of the mRNA targets. Alternatively, it is possible 
that combinations of miRNAs from the C19MC are required for optimal effects. Past experiments 
using clusters of different miRNAs or cells stably expressing the entire C19MC were consistently 
antiviral.  
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4.1.2 Autophagy and viral infections 
In our previous studies, we demonstrated that the C19MC miRNAs confer viral resistance through 
the induction of autophagy. Furthermore, RNAi mediated knockdown of Beclin 1, a known 
component of the autophagic machinery, or pharmacological inhibition of autophagy using 3-MA, 
which inhibits phosphatidylinositol 3 kinases (PI-3K), restored viral infection in cells stably 
expressing the C19MCs [275]. Additionally, we observed increased infection of VSV in PHT cells 
exposed to 3-MA. Interestingly, the HIV protein NEF is known to inhibit autophagy, by binding 
to Beclin 1 [348]. This subversion of the autophagic pathway enhances virion production [349]. 
This could explain the observed difference between the significant reduction in HIV infection with 
exposure to conditioned medium, but not by the introduction of miR-517-3p.  
While HIV has been shown to antagonize the autophagy pathway, VZV is known to induce 
and benefit from autophagy [318, 350]. Therefore it was surprising that transfection of miR-517-
3p into cells exposed to VZV was able to confer resistance (Figure 2-3B). It is possible that the 
pathway being induced by the C19MCs may differ from the canonical autophagy pathway, and 
could be unique and placenta-specific. VZV infection stimulates autophagy through ER stress and 
the unfolded protein response resulting from production of the VZV glycoprotein [350]. 
Interestingly, VZV also lacks ICP34.5 and US11, two HSV viral proteins known to antagonize the 
autophagic pathway [350], again suggesting a non-canonical autophagy pathway is being induced 
by the C19MC miRNAs.  
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4.1.3 C19MC miRNA target identification 
The functions of the vast majority of miRNAs are largely unknown, due to the poorly established 
links between miRNA and their target mRNAs. Some individual miRNAs have been connected to 
certain regulatory pathways, involved in differentiation, development, organ function, and disease 
[226, 351, 352]. However, these represent the exception, rather than the rule. Sequence 
complementarity is restricted to the seed sequence, 6 base pairs at the 5’ region [353], resulting in 
multiple potential target mRNAs and limiting the accuracy of target predictions algorithms [354-
358]. 
Recently, attempts have been made to identify direct targets through the use of cross linked 
immune-precipitation, using the Ago2 protein attached to both the miRNA and the target mRNA 
sequence [359-362]. In addition to these pull-down methods, overexpression or deletion of specific 
miRNAs and the subsequent effect on transcripts can be used to identify potential targets. 
However, these latter types of studies do not necessarily demonstrate direct miRNA targeting to 
mRNAs. The characterizations by transcript could reflect indirect interactions, with miRNAs 
targeting upstream regulators. Additionally, experiments employing specific knockout of 
individual miRNAs commonly do not seem to produce a phenotype, presumably due to the 
redundancy among miRNA species. 
Ongoing research in our lab focuses on identifying potential targets, utilizing cross-linked 
immune precipitation techniques to isolate and identify Ago2 bound miRNA complexes in 
association with their target transcripts [360]. These studies have the benefit of identifying direct 
miRNA:mRNA target interactions, and should provide clues to the role the C19MCs play in 
autophagy induction, and whether this pathway is distinct from canonical autophagy pathways. 
With the identification of the target transcripts, we can then address the possibility that certain 
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pathogens linked to perinatal infections have developed mechanisms to attenuate this pathway. 
Furthermore, these studies may elucidate other regulatory functions of C19MCs, including a 
potential role in placental development and regulation of extravillous trophoblasts invasion [267]. 
4.1.4 Exosomes and communication of antiviral signals 
Based on our previous findings, we know that exosomes derived from the PHT conditioned 
medium are able to confer viral resistance to recipient non-placental cells. This function is specific 
to the exosomes, with apoptotic bodies and microvesicles derived from PHT cells exhibiting a 
much weaker effect (Appendix B, Figure 4-6). As discussed in section 1.4.3.3, extracellular 
vesicles are known to be involved in cell-cell communication. However, we currently do not know 
which tissues are targeted by these vesicles. Furthermore, the critical mass required for exosomes 
and their miRNA cargo to induce antiviral effects remains unclear. MiRNA copy number per 
exosome is variable, and the concentration of exosomes being taken up per recipient cell is 
unknown [363]. Other areas of ongoing research in the lab are focused on deciphering the 
exosome-mediated viral resistance. As demonstrated in appendix B, we have observed a 
significant inhibition of viral infection in cells exposed to exosomes. Comparative analysis of the 
different extracellular vesicles has revealed unique proteins that are present in the exosomes, which 
may affect cellular uptake by the recipient cells, such as the endogenous retroviral encoded protein 
Syncytin-1 [364]. Enhanced cellular uptake of exosomes may explain the unique antiviral effects, 
potentially due to more efficient loading of the miRNAs into the right cellular compartment. 
Recent studies have demonstrated concentrated uptake of exosomes through the certain cellular 
pathways, such as uptake via filopodia of certain cells [365]. Furthermore, what cells are being 
targeted by the exosomes, and what those targeting elements are remain to be determined. It is 
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possible that proteins exclusively expressed by the exosomes, unlike the other extracellular 
vesicles derived from the PHTs is mediating the uptake, but could also be due to unique lipid 
signatures present in the exosomes.  
 So far we have been unable to determine if exosomes have effects that are independent of 
miRNAs. Generating miRNA-free exosomes derived from PHT cells or trophoblast cell lines has 
remained a challenge, as we still do not fully understand the regulatory mechanisms of the 
C19MCs. Ongoing work in the lab is focused on understanding what these regulatory factors are, 
particularly examining the function of C19MC enhancer elements. Interestingly, transgenic mice 
that express a BAC containing the entire 100kb C19MC cluster also demonstrate restricted 
expression in the placenta (unpublished work). Identification either enhancer or repressor 
sequences regulating the expression of the C19MC will enable us to silence the entire cluster. 
Furthermore, ongoing experiments in the lab will uncouple the C19MCs and the exosomes, 
generating type III endonuclease Drosha knockout cells, and isolating vesicles from these cells for 
comparison in functional assays.  
Our data also demonstrated that the conditioned medium from PHT cells had no significant 
impact on the infection of either T. gondii or L. Monocytogenes. This suggests that the conditioned 
medium and the miRNAs are specifically antiviral. Other groups have used a combination of in 
vitro studies and explant models to demonstrate the role of syncytiotrophoblasts in protecting the 
fetus from infection by these pathogens [38, 218]. Given that the CM and C19MCs do not confer 
resistance to these pathogens, it suggests that the trophoblasts have additional, as yet undefined 
mechanisms to resist bacterial and parasitic infections. While some proposed mechanisms of 
resistance have included lack of required pathogen receptors, such as E-cadherin, it is likely that 
there are additional mechanisms involved [5]. We initially utilized unbiased biochemical 
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approaches in the identification of factors present in our conditioned medium that were conferring 
viral resistance as well as ISG induction (figure 3-1). While these studies strongly indicated the 
presence of a protein band corresponding to IFNλ (~25kd), they were discontinued due to 
alternative methods available at the time. However, it is likely that the PHT cells release many 
other factors into the conditioned medium, some of which may be antimicrobial. Future studies to 
continue the biochemical identification of these factors will couple different methods of protein 
biochemistry and gel filtration with functional assays and mass spectrometry to identify potential 
anti-microbial factors.  
4.2 PLACENTAL PRODUCTION OF IFNΛ1 
In appendix A we present data demonstrating that the primary human trophoblasts are resistant to 
ZIKV infection, and that this resistance can be conferred to non-placental recipient cells (figure 4-
2). PHT cells constitutively produce the type III IFN, IFNλ, which robustly induces antiviral 
effector proteins, leading to a cellular state refractory to viral infection. As was mentioned in 
section 1.2.2.4, a few groups have previously noted that the placenta produced an IFN that was not 
neutralized by anti-sera for type I IFNs [117]. Here, we demonstrate that PHT cells, and trophoblast 
cell lines produce IFNλ constitutively and in response to PRR agonists, respectively. These 
findings further support the role of the syncytiotrophoblasts as a crucial barrier to viral infection 
during pregnancy.  
Animal models of pregnancy have indicated the role of IFN in maintaining the conceptus. 
Ruminant and ungulate species, such as bovine, produce a unique pregnancy related IFN, known 
as IFNτ, which has also been demonstrated to be constitutively expressed during pregnancy [366]. 
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However, humans do not have an IFNτ ortholog. In the porcine conceptus, early during gestation 
IFNδ is produced, functioning similarly to other type I interferons [366]. Like IFNτ, IFNδ is also 
not expressed in humans, thought to have been lost over evolution, potentially due to redundancy.  
In the mice, at the site of implantation, some ISGs have been demonstrably up-regulated, including 
ISG15, indicating the role of IFNs during murine pregnancy as well [367]. 
While these examples from other species highlight a functional role for IFN in maintaining 
pregnancy, it is difficult to draw comparisons to human pregnancy. As was discussed in the 
introduction, there are a number of differences between human pregnancy and pregnancy in other 
mammals, including placentation. Furthermore, humans do not encode the above mentioned IFNs, 
while mice lack the gene for IFNλ1, which we have shown to be highly expressed in term human 
trophoblasts.   
4.2.1 IFNλ regulation in the placenta 
The type III IFNs, discussed in section 1.3, are an important component of the innate immune 
system in epithelial cells and endothelial cells. Syncytiotrophoblasts, like other epithelial barriers, 
are polarized cells constantly exposed to pathogenic microbes. The trophoblasts are unique in that 
they constitutively produce IFNλ, in the absence of viral infection. We have previously 
demonstrated that neither NFκB nor IRF3 translocate to the nucleus in PHT cells [275]. It is 
possible that expression of the IFNλs results from global transcription of chromosome 19, which 
contains many pregnancy related genes, including the α subunit of hCG [368], and pregnancy 
specific glycoproteins (PSGs) [369]. Both the chromosome 19 miRNA cluster (C19MC), located 
at chromosome 19q13.41, and the IFNλ genes, located at chromosome 19q13.13, are highly 
expressed in primary human trophoblasts. Alternatively, high expression of IFNλ could be related 
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to the fusion of the cytotrophoblasts as they differentiate to syncytiotrophoblasts. This hypothesis 
is attractive, since we have demonstrated that differentiation of the trophoblasts was necessary for 
the ability of CM to induce ISGs in recipient cells, presumably through the expression of IFNλ.  
4.2.2 Viral entry into the fetal compartment  
Our group and others have shown that the placenta is a remarkably efficient barrier to infection, 
conferring protection against most pathogens. In particular we have demonstrated that the 
syncytiotrophoblasts, through high levels of basal autophagy and autocrine signaling of IFNλ, 
create a formidable barrier to pathogens. However, despite these barrier functions, certain viral 
pathogens can lead to severe disease in the fetus. Here, we will discuss the potential routes of viral 
access to the fetus.  
4.2.2.1 First and second trimester trophoblasts  
We have shown that primary human trophoblasts from term placentas are remarkably resistant to 
viral infection. Recent studies from other groups have begun to address whether or not trophoblasts 
from earlier periods during gestation are as efficient at preventing infection from viruses, such as 
ZIKV [48]. Considering that many perinatal infections early during pregnancy manifest in severe 
congenital defects, such as microcephaly and other developmental abnormalities, it is possible the 
placenta during early gestational periods in gestation is not as effective as a fully developed 
placenta at term.  Alternatively, these early gestational periods are the most critical for fetal 
development, and it is possible that similar magnitudes of fetal infection may lead to more dramatic 
consequences for the fetus during these initial stages. As was discussed in section 1.3, primary 
infection during the first trimester of pregnancy by viruses including CMV, rubella, and VZV, may 
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cause congenital syndromes, while infections during later periods of pregnancy is less frequent, or 
cause less severe disease. Recent reports on ZIKV suggest that infection early in gestation leads 
to intrauterine growth restriction (IUGR), microcephaly, and malformation of the fetal brain [209, 
330]. Using first trimester placental explants, the Pereira group demonstrated that ZIKV infects 
cytotrophoblasts, endothelial cells, fibroblasts, Hofbauer cells from chorionic villi, and amniotic 
epithelial cells [48], but that the syncytiotrophoblasts had no detectable virus. They also 
demonstrated that ZIKV titers were significantly higher in amniotic cells isolated from mid-
gestation, 16-23 weeks of pregnancy, compared to those isolated from later gestational periods, at 
term [48]. At these later periods, the fetus may be less susceptible to developmental injuries, as 
many of the tissues are already formed.  
It is important to note that the placenta does not become perfused with maternal blood until 
12 weeks of pregnancy, when the placental plugs of the maternal spiral arteries begin to degrade. 
These plugs are comprised of extravillous columnar cells, and may be susceptible to viral infection, 
similar to what has been demonstrated for the EVTs, mentioned above. Future studies to address 
the susceptibility of these cells can utilize induced pluripotent stem cells to recapitulate the in vivo 
phenotype of these columnar cells, and provide a model for primary infection early in gestation.  
4.2.2.2 Routes of virus infection 
While the syncytiotrophoblasts are refractory to viral infection, it has been previously reported that 
viruses bound by maternal IgG can be transported across the placental barrier via neonatal FC 
receptor. This was shown for hCMV, as IgG-virion complexes crossed via transcytosis in explant 
models [370]. This mechanism may be utilized by ZIKV to gain access to the fetus. Dengue virus 
is endemic in Brazil, and large portions of the population are sero-positive, including women of 
childbearing age. Recent reports have indicated that the four different sero-types for DENV are 
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cross reactive to ZIKV [371, 372], however cross reactivity is not required for ZIKV infection, as 
mothers sero-negative for DENV were infected with ZIKV, and passed the virus to the fetus [209]. 
Exposure to DENV leads generation of antibodies specific for one of the four serotypes. Upon 
exposure to a different serotype the antibodies, which recognize the viral glycoprotein or fusion 
loop epitope (FLE), do not provide protection [371], but instead facilitate entry into cell types that 
would not typically be infected, via the FC receptor. This was recently demonstrated in vitro, as 
DENV plasma potently induced ADE, enhancing ZIKV infection [371]. Therefore, prior immunity 
to DENV may drive greater replication of ZIKV.  
Other groups have demonstrated that cytotrophoblasts, extravillous trophoblasts and 
Hofbauer cells, from first trimester explants are susceptible to a variety of viruses, including CMV 
and ZIKV [35, 48, 373, 374]. We currently don’t know the targets cells that uptake the trophoblast 
exosomes, nor do we know the extent to which IFNλ confers resistance to neighboring cells. Future 
studies will need to explore the expression of IFNLR in the uterine environment.  
4.2.3 IFNλ polymorphisms 
In our studies we have observed variability amongst the placental preparations, regarding the 
derived cells ability to confer viral resistance. Conditioned medium preparations also contained 
variable quantities of IFNλ. These differences in the potency of the antiviral effects could 
potentially reflect differences in the feto-placental genome. Genome wide association studies 
(GWAS) examining differences in response to HCV and HBV infection, indicated that populations 
demonstrating improved outcomes in terms of spontaneous clearance of viral infection as well as 
response to antiviral therapy, contained polymorphisms in the promoter of IFNλ. One allele 
identified corresponded with increased production of IFNλ3, potentially leading to better control 
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of infection [156]. A separate allele demonstrated an altered 3’UTR sequence, rendering the IFNλ3 
less susceptible to miRNA degradation following HCV infection [375].  It is possible that the 
differences we observe amongst the placental cell isolates, and potentially differences in the 
population among women who are more susceptible to viral infection during pregnancy, are due 
to single nucleotide polymorphisms in IFNλ genes. We have observed variability in the potency 
of conditioned medium from different placental preparations. Given that we have noted variability 
in, the antiviral potency of conditioned media, it may be relevant to test our primary human 
trophoblasts for SNPs, and compare the efficacy of the conditioned medium to determine if genetic 
differences are a factor in contributing to susceptibility to fetal infection.  
4.3 CONCLUDING REMARKS 
We have shown that the primary human trophoblasts deploy at least two distinct antiviral 
mechanisms, which can be communicated to non-placental cells. These two pathways are depicted 
in figure 4-1. The PHT derived exosomes, which contain miRNAs from the C19MC, have been 
shown to be antiviral through the induction of autophagy. This induction is presumably through 
classical miRNA shutoff of translation or by transcript degradation. We have previously 
demonstrated that the exosomes are capable of conferring viral resistance in cells deficient in the 
JAK/STAT pathway, and we have demonstrated here (Figure 4-6B) that the exosomes or other 
extracellular vesicles do not lead to an ISG induction. The second pathway is the constitutive 
production of IFNλ and subsequent ISG induction in non-placental recipient cells.  
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Figure 4-1 Parallel paracrine pathways deployed by PHT cells 
  
The multiple mechanisms work in parallel, and it is unclear what, if any, interactions exist these 
two pathways. Other groups have suggested that RNAi and IFN pathways are mutually exclusive 
[376, 377]. Studies have demonstrated that in the presence of type I IFN induction by Poly I:C, 
Ago2 is inhibited, blocking the function of the RISC complex [378].  
The regulation of IFNλ1 expression in the PHT cells is currently unknown, and it is 
possible that there are differences in IFNλ1expression in early and late pregnancy. The gene locus 
for IFNλ 1-4 is adjacent to the locus for the C19MC [150, 301]. It is therefore possible that 
constitutive expression of IFNλ is linked to expression of the C19MC miRNAs, or that they are 
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both regulated by distant enhancer sequences. While the mechanisms underlying the placenta-
specific regulation of the C19MC is not yet known, it is possible that the two pathways share a 
placental-specific genomic activation or repression.  
Understanding how viruses gain access to the fetal compartment is a crucial yet 
understudied area of research. Some of the reasons for our lack of knowledge regarding how 
viruses can circumvent the placental barrier include a lack of adequate models that fully 
recapitulate the events in vivo. Animal models have advantages of being able to model vertical 
transmission of infection, but have the disadvantage of being morphologically and genetically 
different from human placenta. Placental cell lines allow for genetic manipulation and 
characterization of the molecular events of trophoblast infection, such as the production of IFNλ 
in response to ZIKV infection (figure 3-3E). However, these choriocarcinoma cell lines often are 
more characteristic of their carcinoma origins, and do not fully represent the trophoblasts in vivo. 
Explant models of first and second trimester villi have facilitated the study of early events of 
infection during pregnancy. However, these tissue samples are difficult to attain. Future advances 
in the available models will provide better understanding of the role of the placenta in protecting 
the fetus against infection, and mechanisms by which the pathogens are able to access the fetus.  
In the remaining sections of the dissertation, we provide evidence for PHT resistance to 
ZIKV infection (appendix A), and the ability of the PHT conditioned medium to confer resistance 
to non-placental cells. This work directly ties in with the findings presented in chapter 3, as IFNLR 
knockdown by RNAi restored ZIKV infection in cells exposed to conditioned medium (figure 3-
3G).  In appendix B, we provide preliminary evidence in support of the model presented in figure 
4-1, demonstrating that the exosome mediated C19MC pathway and the IFNλ pathway presented 
in this work are independent of one another.  
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APPENDIX A 
PHT CELLS ARE REFRACTORY TO ZIKA VIRUS11  
Data for Appendix A was generated by Nicholas Lennemann and Carolyn Coyne 
 
To assess the ability of ZIKV to replicate in human placental trophoblasts, we measured the 
replication of two strains of ZIKV, one of African lineage [336] (MR766, termed ZIKVM hereafter) 
and one of Asian lineage [336] (FSS13025, termed ZIKVC hereafter) in PHT cells and a panel of 
trophoblast-derived cell lines including BeWo, JEG-3, and JAR choriocarcinoma cells, and the 
extravillous trophoblast cell line HTR8/SVneo [50]. In addition, we compared the level of 
infection of these cell types by DENV. We also compared the infectivity of these cell types with 
that of human brain microvascular endothelial cells (HBMEC), which is a cell-based model of the 
blood-brain barrier [379] and is permissive to DENV and both strains of ZIKV (Figure 1A, Figure 
S1A)12. We found that BeWo, JEG-3, JAR, and HTR8/SVneo cells supported infection by both 
ZIKVM and ZIKVC, although BeWo cells were less susceptible to infection by both DENV and 
ZIKV than the other trophoblast-derived cells lines (Figure 3-1A and Figure 3-5A).  
In contrast, we were unable to detect any evidence of ZIKV or DENV replication in PHT 
cells by immunofluorescence microscopy (not shown). Consistent with this, we found that PHT 
                                                 
11 Reprinted with permission from Cell publishing 
12 Data for ZIKV infection assays was provided by Dr. Carolyn Coyne and Dr. Nicholas 
Lennemann (University of Pittsburgh, Pittsburgh PA) 
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cells resisted infection by ZIKVM, ZIKVC, and by DENV, as evidenced by very low levels of total 
viral RNA (vRNA) (Figure 3-5B and 3-5C)4 and the lack of production of the negative strand of 
vRNA, which is only produced during viral replication (Figure 3-1B)4.  These results are consistent 
with our previous observations that PHT cells resist infection by diverse RNA and DNA viruses 
[275] and show that ZIKV is unable to replicate efficiently in primary trophoblasts. 
 
 
Figure 4-2 PHT cells are resistant to ZIKV (A), The indicated cell lines were infected with DENV, ZIKVM, or 
ZIKVC for ~24hrs, fixed, and then stained with anti-dsRNA (J2) antibody. Data are shown as the percent of 
vRNA positive cells relative to the total number of nuclei (as assessed by DAPI). (B), Levels of DENV, ZIKVM, 
or ZIKVC negative strand vRNA were assessed by RT-qPCR in non-PHT (HBMEC) or PHT cells infected for 
~48hrs. (C), HBMEC were exposed to non-conditioned (NCM) PHT medium or conditioned PHT medium (CM, 
two independent preparations) for ~24hrs and then infected with DENV, DENV, ZIKVM, or ZIKVC. The level 
of infection was assessed for fluorescence microscopy for dsRNA. Data are shown as the percent of vRNA 
positive cells relative to the total number of nuclei (as assessed by DAPI). (D), Control HeLa cells, or HeLa cells 
constitutively expressing a DENV replicon were exposed to NCM or three independent preparations of PHT 
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CM and then the levels of DENV vRNA assessed by RT-qPCR ~24hrs after exposure. In all, data are shown as 
mean  ± standard deviation (*p<0.05, **p<0.01, ***p<0.001). Data related to figure 3-1(A-D) was provided by 
Dr. Nicholas Lennemann and Dr. Carolyn Coyne (University of Pittsburgh, Pittsburgh PA)  
 
 
Figure 4-3 Supplemental data related to Figure 4-2. (A), RT-qPCR for total vRNA in the indicated DENV or 
ZIKVM infected trophoblast cells lines, or in HBMEC. Data are shown as a fold from HBMEC. (B,C), RT-
qPCR for total vRNA in DENV, ZIKVM, or ZIKVC infected PHT cells, or in HBMEC (B) or JEG-3 (C) cells. 
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Data are shown as a fold from HBMEC (B) or JEG-3 (C). (D), Transmission electron micrograph (TEM) from 
HeLa cells stably expressing a DENV replicon. White arrows denote DENV-induced replication organelles. 
Scale, 500 nm, at bottom right. (E), RT-qPCR for DENV vRNA in HeLa cells stably expressing a DENV 
replicon and transfected with a control 
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APPENDIX B 
CHARACTERIZATION OF TROPHOBLAST EXTRACELLULAR VESICLES ON ISG 
INDUCTION AND ANTIVIRAL EFFECTS 
B.1 INTRODUCTION 
Primary human trophoblasts have previously been shown to confer viral resistance to non-
placental cells, through the release and subsequent uptake of extracellular vesicles, that contain 
miRNAs from the C19MC family of miRNAs [275]. Based on our results from chapter 3, we know 
that the PHT cells, in addition to the release of the extracellular vesicles, constitutively produce 
type III interferon, IFNλ1. In this section, we assessed the potential synergy between miRNA 
pathways to observed ISG induction in recipient cells, as well as further characterizing the PHT 
derived extracellular vesicles. While previous studies examined the role of the exosomes from 
PHT cells, here we expand the panel of extracellular vesicles to include apoptotic bodies as well 
as microvesicles, exploring their potential contribution to the observed antiviral phenotype.  
Additionally, we address the questions about potential interaction between the two 
pathways, combining both extracellular vesicles with recombinant IFNλ1 in recipient cells. We 
found no significant interaction between these two pathways.   
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B.2 RESULTS 
B.2.1 Extracellular vesicles from PHT cells inhibit viral infection but do not induce ISGs 
We added individually isolated extracellular vesicles, including apoptotic bodies, microvesicles, 
and exosomes, to U2OS cells for approximately 18 h prior to infection with VSV. Figure 4.5A 
demonstrates that isolated conditioned medium and exosomes showed significant reduction in 
VSV infection, while apoptotic bodies and microvesicles reduced infection, but not significantly. 
The antiviral activity of the vesicles was independent of the IFNλ activity reported in chapter 3, as 
isolated vesicles added to recipient U2OS inhibited viral infection but did not induce IFI44L, while 
conditioned medium used as the source for those vesicles did significantly induce IFI44L (Figure 
4.6B).  
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Figure 4-4 - Extracellular vesicles from PHT cells and their effects on VSV and ISG induction. Extracellular 
vesicles from primary trophoblast cells were tested for their effects on VSV replication and ISG induction in 
U2OS cells. Viral replication and ISG induction were measured using qPCR, as described in the methods. 
Vesicles were prepared from PHT cells from three different placental preparations. Analysis was performed 
using one-way ANOVA (Prism 6.0 software). The asterisks indicate statistical significance. * denotes p<0.05. 
 
B.2.2 Extracellular vesicles and IFNλ are independent pathways 
To address whether there is any interaction between the two pathways reported in chapters 2 and 
3, we combined isolated extracellular vesicles from PHT cells, which did not have any ISG 
induction on their own, with recombinant IFNλ1. Conditioned medium, isolated vesicles, and IFNλ 
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independently inhibited VSV infection to a variable degree. When IFNλ was combined with 
isolated vesicles there was no significant change in VSV infection, suggesting no interaction 
between the two pathways (4.7A). Furthermore, ISGs measured in cells exposed to CM, isolated 
vesicles, IFNλ, or a combination of the vesicles with IFNλ, again did not demonstrate any influence 
between the two pathways. ISG induction, measured for IFI44L (Figure 4.7B), IFIT1 (Figure 
4.7C), or OAS1 (Figure 4.7D), do not indicate any change in expression from IFNλ with the 
addition of either microvesicles or exosomes.  
 
Figure 4-5 - Interaction between trophoblast vesicles and IFNλ1. (A) VSV infection was measured in U2OS 
cells exposed to Mock (untreated cells), PHT CM, or IFNλ1 with or without the addition of PHT derived 
microvesicles or exosomes. Cells were exposed for 24 h prior to infection, and infection was measured by RT-
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qPCR. (B-D) ISG induction was measured in the cells exposed to IFNλ1 (10 ng/ml) with the addition of either 
isolated microvesicles or exosomes derived from PHT cells. ISG induction was quantified by RT-qPCR.  
B.3 MATERIALS AND METHODS 
B.3.1 Cells and Viruses 
Human osteosarcoma U2OS cells were cultured in DMEM supplemented with 10% FBS and 
antibiotics.  
For viral infection assays, U2OS cells were seeded into 24 well plates. 24 h following 
plating, the cells were infected with vesicular stomatitis virus (VSV) at the multiplicity of infection 
(MOI) equivalent to 0.5-1, for 5 h, and then washed three times with PBS, to remove residual non-
infected virus.  
B.3.2 RNA extraction, cDNA synthesis, and Real-Time quantitative PCR 
For cellular mRNA analysis, total RNA was extracted using TRI reagent (MRC) RNA samples 
were processed with RNase-free DNAse (Qiagen or Sigma). Total RNA was reverse transcribed 
using HiCapacity cDNA synthesis kit (Applied Biosystems) RT-qPCR was performed using 
SYBR select in a ViiA7 system (Applied Biosystems). Gene expression was calculated using the 
2-delta delta CT method normalized to GAPDH. Primer sequences were GAPDH (5’- 
GAAGGTCGGAGTCAACGGATTT -3' and 5’- GAATTTGCCATGGGTGGAAT -3') and 
IFI44L (5’-TGCAGAGAGGATGAGAATATC-3' and 5’-ACTAAAGTGGATGATTGCAG-3'); 
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IFIT1 (5’-CAACCAAGCAAATGTGAGGA-3' and 5’-GGAGACTTGCCTGGTGAAAA-3'); 
OAS1 5’-ATAAAAGCAAACAGGTCTGG-3’ and 5’- TCTGGCAAGAGATAGTCTTC-3’).  
 
 
B.3.3 PHT conditioned medium and isolated vesicle preparations 
CM samples from PHT cells were harvested at 72h after plating followed by centrifugation at 800 
xg for 5 min. Non-conditioned medium (NCM) was complete PHT medium (described above) that 
had not been exposed to PHT cells. Recipient cells were exposed to either conditioned medium or 
filtered fractions for ~24 h before assays. 
PHT cells were cultured in 7x15-cm plates at 37° for 72 h in complete DMEM containing 
1% antibiotics and 10% fetal bovine serum depleted of exosomes by overnight ultracentrifugation. 
Approximately 400 mL of conditioned medium was collected per vesicles purification. Serial 
centrifugation steps, including an initial spin at 500g for 10 min to remove cell debris, followed 
by 2,500g for 20 min to pellet and isolated the apoptotic bodies. These were washed three times 
with PBS, and resuspended in 50-100 μL of PBS (Sigma). Supernatant from the preceding step 
was then spun at 12,000g for 30 min to pellet and isolate the microvesicles. These were washed 
three times in PBS and resuspended. The supernatant from the preceding step was then used for 
exosome isolation. The supernatant was spun at 100,000 xg overnight. This supernatant was 
removed, and he pellet was resuspended in 0.5 mL PBS mixed with 1.5 mL OptiPrep 60% (Sigma 
Aldrich). This mixture was placed at the bottom of a tube, and overlayed with 6-40% OptiPrep 
gradient, using a gradient formation chamber and peristaltic pump. The mixture was spun at 
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100,000 xg for 22h, and fractions containing exosomes were isolated and confirmed by western 
blot.  
B.4 CONCLUSIONS 
We have previously demonstrated that exosomes isolated from medium that was conditioned by 
primary human trophoblast are capable of conferring viral resistance to non-placental recipient 
cells. Here we have shown that the PHT-exosomes significantly reduced viral infection in U2OS 
cells, compared to the other extracellular vesicles (EV) derived from the PHT cells, which reduced 
infection to a lesser extent (Figure 4.6A). Furthermore, based upon the results presented in chapter 
3, we know that conditioned medium from PHT cells can induce ISGs robustly in recipient cells. 
Here we have confirmed that this ISG induction was independent of the extracellular vesicles, and 
likely exclusively mediated by IFNλ1 (Figure 4.6B).  This strongly suggests that the two antiviral 
pathways, discussed in chapter 2 and chapter 3, are independent of one another.  
To further explore the relationship between the antiviral activity of EVs and IFNλ, we 
incubated recipient cells for 24h with EVs, IFNλ, or the two combined, and measured the effects 
on VSV infection and ISG induction. In support of the findings from figure 4.6, the EVs did not 
induce ISGs, but were antiviral. IFNλ was both antiviral and strongly induced ISGs, as expected. 
Interestingly, the combination of EVs with IFNλ did not cause any noticeable synergistic effect. 
This strongly suggests that the two pathways act independently, with no evidence for a synergistic 
relationship or cross talk between them. As was mention in chapter 4, other groups have suggested 
that the IFN pathway blocks RNAi, and the two pathways are mutually exclusive. Future studies 
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will explore the relationship between the C19MC miRNAs and IFNλ1, including any potentially 
shared regulation, and also for any potential negative feedback between the two pathways.  
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